UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of
1934
Date of
Report (Date of Earliest Event Reported): March 30,
2018
MetaStat, Inc.
(Exact
name of registrant as specified in its charter)
Nevada
(State
or other jurisdiction of incorporation)
000-52735
(Commission File
Number)
|
20-8753132
(IRS Employer
Identification No.)
|
27 Drydock Ave., 2
nd
Floor
Boston, Massachusetts 02210
(Address
of principal executive offices and zip code)
(617) 531-6500
(Registrant's
telephone number including area code)
(Registrant's
former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of registrant under
any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12(b) under the Exchange
Act (17 CFR 240.14a-12(b))
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01. Entry into a Material Definitive
Agreement.
On
March 30, 2018, MetaStat, Inc. (the “
Company
”) entered into a
note purchase agreement (the “
Note Purchase Agreement
”)
with a number of institutional and accredited investors
(collectively, the “
Purchasers
”), pursuant to
which the Company may sell in a private placement (the
“
Private
Placement
”) up to an aggregate purchase price of
$3,628,927 (the “
Purchase Price
”),
consisting of
(i) senior
non-convertible promissory bridge notes in the aggregate principal
amount of up to $2,334,027 (the “
Senior
Notes
”), (ii) junior
non-convertible promissory bridge notes in the aggregate principal
amount of $1,294,900 (the “
Junior
Notes
” and, together with
the Senior Notes, the “
Notes
”),
and (iii)
warrants (the “
Note Warrants
”)
exercisable to purchase ten thousand (10,000) shares of the
Company’s common stock, par value $0.0001 (the
“
Common
Stock
”) per share, for each $100,000 principal amount
of Notes issued on a pro rata basis, at an exercise price equal to
$2.00 per share, for a term of five (5) years
.
Pursuant to an exchange agreement dated
March 30, 2018
(the “
Exchange
Agreement
”), the existing
holder of the outstanding
10% convertible promissory note in
the aggregate principal amount of $1,000,000, plus all accrued and
unpaid interest thereon, which matured on September 30, 2017,
originally issued by the Company pursuant to that certain exchange
agreement dated January 17, 2017 (the “
Promissory Note
”),
exchanged the Promissory Note (the “
Promissory Note
Exchange
”) for a Senior Note with a principal amount
of $834,027 and 83,304 Note Warrants pursuant to the Note Purchase
Agreement. Further, the Company repaid $300,000 of the outstanding
balance of the Promissory Note concurrent with the
closing.
Additionally,
pursuant to the Exchange Agreement,
the holder of (i)
shares of the
Company’s Series B Convertible Preferred Stock with a stated
value of $5,500 per share, plus all accrued and unpaid dividends
thereon (the “
Series
B Preferred
”), and (ii) five-year warrants to purchase
91,000 shares of Common Stock at an exercise price of $10.50 per
share (the “
Series A
Warrants
”), originally issued by the Company pursuant
that certain securities purchase agreement dated December 31, 2014,
as amended March 27, 2015, exchanged the Series B Preferred and the
Series A Warrants (the “
Series B Exchange
” and,
together with the Promissory Note Exchange, the “
Exchange
”) for a Junior
Note with a principal amount of $1,294,900 and 129,490 Note
Warrants pursuant to the Note Purchase Agreement.
The Notes mature on September 30, 2018, accrue interest at a rate
of ten percent (10%) per annum and may not be prepaid by the
Company prior to the maturity without the consent of the
holder. The principal amount plus all accrued and unpaid
interest thereon shall
automatically exchange (the
“
Automatic
Exchange
”), without any action of the holder, into
such number of fully paid and non-assessable securities (e.g.
shares and warrants) to be issued in a Qualified Offering.
“
Qualified
Offering
” means one or a series of offerings of equity
or equity-linked securities resulting in aggregate gross proceeds
of at least $6,628,927 to the Company, including the Automatic
Exchange of the Notes into the Qualified Offering.
The
Senior Note and the Junior Note are in substantially similar form,
provided
,
however
, that the Senior Note shall
rank senior to the Junior Note with respect to payment. The Notes
shall rank senior to all future indebtedness of the Company and to
the Company’s issued and outstanding equity
securities,
except as
otherwise required by applicable law.
Pursuant to the Notes, the Company shall not, without first
obtaining the consent of the holder (which consent will not be
unreasonably withheld), incur any new indebtedness while the Notes
are outstanding, except no consent shall be required in connection
with indebtedness incurred by the Company in the ordinary course of
business or from any strategic investors. In addition,
so long as the Notes are outstanding, the Company shall not create
or impose any material lien upon any material property or assets
(including intellectual property) of the Company or any of its
subsidiaries except for Permitted Liens (as defined in the Note
Purchase Agreement).
The
Note contains the following event of default
provisions:
●
the failure to pay
principal or interest within ten business days after such amounts
are due;
●
any material breach
by the Company of any representations or warranties made in the
Notes;
●
the holder of any
indebtedness of the Company shall accelerate any payment of any
amount on any such indebtedness, the aggregate principal amount of
which indebtedness is in excess of $500,000, and such indebtedness
has not been discharged in full or such acceleration has not been
stayed, rescinded or annulled within fifteen (15) business days of
such acceleration;
●
a judgment for the
payment of money shall be rendered against the Company for an
amount in excess of $500,000 in the aggregate for all such
judgments that shall remain unpaid for a period of sixty (60)
consecutive days;
●
Company files any
petition or action for relief under any bankruptcy or makes any
assignment for the benefit of creditors or an involuntary petition
is filed against the Company under any bankruptcy statute now or
hereafter in effect, and such petition is not dismissed or
discharged within 45 days; or
●
A proceeding or
case shall be commenced in respect of the Company without its
application or consent, in any court of competent jurisdiction,
seeking (i) its liquidation, dissolution or winding up, (ii) the
appointment of a trustee or the like of it or of all or any
substantial part of its assets or (iii) similar relief in respect
of it under any law providing for the relief of debtors, and such
proceeding or case described shall continue undismissed, or
unstayed and in effect, for a period of forty-five (45) consecutive
days or any order for relief shall be entered in an involuntary
case under the Bankruptcy Code or under the comparable laws of any
jurisdiction (foreign or domestic) against the Company or any of
its subsidiaries and shall continue undismissed, or unstayed and in
effect for a period of forty-five (45) consecutive
days.
Pursuant to the closing of the Private Placement and Exchange on
March 30, 2018, the Company issued (i) Senior Notes in the
aggregate principal amount of approximately $2,084,028, including
$834,027 from the Promissory Note Exchange, (ii) Junior Notes in
the aggregate principal amount of approximately $1,294,900 solely
pursuant to the Series B Exchange, and (iii) an aggregate of
337,894 Note Warrants for an aggregate Purchase Price of
approximately $3,378,928, including the Exchange.
After
deducting placement agent fees and other offering expenses, the
Company received net proceeds of approximately $1.13 million prior
to the repayment of $300,000 of the Promissory Note. Additionally,
the Company will issue an aggregate of 86,957 placement agent
warrants with a term of five years, an exercise price equal to
$1.27 per share, and a cashless exercise provision.
Pursuant to the Exchange, the Promissory Note and the Series B
Preferred stock have been cancelled and are no longer
outstanding.
The
foregoing description of the Private Placement and related
transactions does not purport to be complete and is qualified in
its entirety by reference to the complete text of the (i) form of
Note Purchase Agreement filed as Exhibit 10.1 hereto; (ii) form of
Exchange Agreement filed as Exhibit 10.2 hereto, (iii) form of
Senior Note filed as Exhibit 4.1 hereto, (iv) form of Junior Note
filed as Exhibit 4.2 hereto, and (v) form of Note Warrant filed as
Exhibit 4.3 hereto.
The
issuance of the securities pursuant to the Private Placement and
the Exchange were exempt from registration pursuant to Section 4(2)
of, and Regulation D promulgated under, and Section 3(a)(9) of, the
Securities Act of 1933, as amended.
Item 2.03. Creation of a Direct Financial
Obligation.
The
disclosure set forth under Item 1.01 above is hereby incorporated
in its entirety under this Item 2.03.
Item 3.02. Unregistered Sales of Equity
Securities.
As
described more fully in Item 1.01 above, the issuance of
securities pursuant to the Private Placement and the Exchange were
exempt from registration pursuant to Section 4(2) of, and
Regulation D promulgated under, and Section 3(a)(9) of, the
Securities Act of 1933, as amended. The securities
issued in the Private Placement and the Exchange have not been
registered under the Securities Act or any other applicable
securities laws, and unless so registered, may not be offered or
sold in the United States except pursuant to an exemption from the
registration requirements of the Securities Act.
Item 9.01.
Financial Statement and
Exhibits.
(d)
Exhibits.
Exhibit
No.
|
|
Description
|
|
|
|
|
|
Form of
Senior Note.
|
|
|
|
|
|
Form of
Junior Note.
|
|
|
|
|
|
Form of
Note Warrant.
|
|
|
|
|
|
Form of
Note Purchase Agreement.
|
|
|
|
|
|
Form of
Exchange Agreement.
|
|
|
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
|
METASTAT,
INC.
By:
/s/ Douglas A.
Hamilton
Name:
Douglas A. Hamilton
Title:
President and CEO
|
Exhibit 4.1
THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE
SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE
DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER
APPLICABLE STATE SECURITIES LAWS OR UNLESS METASTAT, INC. SHALL
HAVE RECEIVED AN OPINION OF COUNSEL THAT THE REGISTRATION OF SUCH
SECURITIES UNDER THE SECURITIES ACT AND UNDER THE PROVISIONS OF
APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED.
METASTAT, INC.
Senior Non-Convertible Promissory Bridge Note
U.S.
$[________]
No.:
[_______]
|
Issuance
Date: [__], 2018
Maturity
Date: [Six (6) Months Following the Issuance Date]
|
FOR VALUE RECEIVED
, MetaStat, Inc., a
Nevada corporation (the “
Company
”), hereby
promises to pay to the order of [___________] or any permitted
holder (the “
Payee
”) of this senior
non-convertible promissory bridge note (this “
Note
”), at the principal
office of the Payee set forth herein, or at such other place as the
Payee may designate in writing to the Company, the principal sum of
[___________] Dollars ($[_____]), with interest on the unpaid
principal balance hereof at a rate equal to ten percent (10%) per
annum commencing effective as of the Issuance Date (the
“
Commencement
Date
”), in such currency of the United States of
America as at the time shall be legal tender for the payment of
public and private debts and in immediately available funds, as
provided in this Note. This Note has been entered into pursuant to
the terms of a note purchase agreement (the “
Purchase Agreement
”)
dated as of [_____], 2018 by and among the Company and the
purchasers signatory thereto. Unless otherwise separately defined
herein, each capitalized term used in this Note shall have the same
meaning as set forth in the Purchase Agreement.
1.
Principal, Interest and
Prepayment
.
(a)
The Company shall
repay the entire principal balance plus accrued and unpaid interest
thereon (the “
Outstanding Balance
”)
then outstanding under this Note no later than [six (6) months
following the Issuance Date] (the “
Maturity
Date
”).
(b)
Interest on the
outstanding principal balance of this Note shall accrue at a rate
of ten percent (10%) per annum commencing on the Commencement Date,
which interest shall be computed on the basis of the actual number
of days elapsed and a year of three hundred and sixty-five (365)
days. Furthermore, upon the occurrence of an Event of Default (as
defined below), then to the extent permitted by applicable law, the
Company will pay interest to the Payee on the then outstanding
principal balance of the Note from the date of the Event of Default
until this Note is paid in full at the rate of twelve percent (12%)
per annum.
(c)
The Company may not
prepay this Note, either in whole or in part, absent the
Payee’s prior written consent.
2.
Automatic Exchange of Outstanding
Balance upon Qualified Offering
. Subject to the terms and
conditions of this Section 2 and provided this Note remains
outstanding, this Note shall automatically exchange at the
Outstanding Balance (the “
Automatic Exchange
”),
without any action on the part of the Payee, into such number of
fully paid and non-assessable securities (e.g. shares and warrants)
to be issued in the Qualified Offering (as defined below). With
respect to the Automatic Conversion, the Company and/or the
Company’s investment banker(s) shall communicate and provide
notice of the timing, pricing and closing of the Qualified Offering
to the Payee in the same manner as all other investors in the
Qualified Offering. The Payee shall be deemed to be a purchaser in
the Qualified Offering and shall be granted all rights afforded to
an investor in the Qualified Offering and shall enter into such
reasonable definitive documentation with respect to the Qualified
Offering. For purposes of this Note, “
Qualified Offering
” shall
mean one or a series of offerings of equity or equity-linked
securities following the date of this Note, resulting in aggregate
gross proceeds of at least $6,628,927 to the Company, including the
Automatic Exchange of the Notes into the Qualified
Offering.
3.
Rank
. This Note shall rank
senior with respect to payment to all existing and future
indebtedness of the Company including the junior non-convertible
promissory bridge note issued pursuant to the Purchase Agreement
and to the Company’s issued and outstanding equity
securities, except as otherwise required by applicable
law.
4.
Additional Indebtedness
. The
Company shall not, without first obtaining the consent of from the
Payee (which consent will not be unreasonably withheld), incur any
new Indebtedness (indebtedness of the Company which does not exist
as of the date of this Note) while this Note is outstanding;
provided
,
however
, that the
consent of the Payee will not be required with respect to Permitted
Indebtedness.
5.
Prohibition on Liens
. So long
as this Note is outstanding, the Company shall not create or impose
any material Lien of the Company or any of its Subsidiaries
pursuant to the terms of any agreement or instrument to which any
of them is a party or by which any of them may be bound or to which
any of their property or any of them is subject, except for
Permitted Liens. Failure to comply with the terms of this Section 5
shall be deemed an Event of Default pursuant to Section 8 of this
Note.
6.
Non-Business Days
. Whenever any
payment to be made shall be due on a Saturday, Sunday or a public
holiday under the laws of the State of New York, such payment may
be due on the next succeeding Business Day and such next succeeding
day shall be included in the calculation of the amount of accrued
interest payable on such date.
7.
Representations and Warranties of the
Company
. The Company represents and warrants to the Payee as
follows:
(a)
The Company has
been incorporated and is validly existing and in good standing
under the laws of the State of Nevada, with full corporate power
and authority to own, lease and operate its properties and to
conduct its business as currently conducted.
(b)
This Note has been
duly authorized, validly executed and delivered on behalf of the
Company and is a valid and binding obligation of the Company
enforceable against the Company in accordance with its terms,
subject to limitations on enforcement by general principles of
equity and by bankruptcy or other laws affecting the enforcement of
creditors’ rights generally.
(c)
The execution,
delivery and performance of this Note will not: (i) conflict with
or result in a material breach of or a default under any of the
terms or provisions of, (A) the Company’s articles of
incorporation or by-laws, or (B) any material provision of any
indenture, mortgage, deed of trust or other material agreement or
instrument to which the Company is a party or by which it or any of
its material properties or assets is bound; (ii) result in a
violation of any material provision of any law, statute, rule,
regulation, or any existing applicable decree, judgment or order by
any court, Federal or state regulatory body, administrative agency,
or other governmental body having jurisdiction over the Company, or
any of its material properties or assets; or (iii) result in the
creation or imposition of any material lien or encumbrance upon any
material property or assets of the Company pursuant to the terms of
any agreement or instrument to which the Company is a party or may
be bound or to which the Company or any of its property is
subject.
(d)
No consent,
approval or authorization of or designation, declaration or filing
with any governmental authority on the part of the Company is
required in connection with the valid execution and delivery of
this Note.
8.
Events of Default
. The
occurrence of any of the following events shall be an
“
Event of
Default
” under this Note:
(a)
the Company shall
fail to make the payment of any principal amount outstanding for a
period of ten (10) Business Days after the date such payment shall
become due and payable hereunder; or
(b)
the Company shall
fail to make the payment of any accrued and unpaid interest for a
period of ten (10) Business Days after the date such interest shall
become due and payable hereunder; or
(c)
any material breach
by the Company of any representations or warranties made by the
Company herein; or
(d)
the holder of any
Indebtedness of the Company shall accelerate any payment of any
amount or amounts of principal or interest on any such Indebtedness
(other than with respect to this Note and notes of like tenor)
prior to its stated maturity or payment date, the aggregate
principal amount of which Indebtedness is in excess of $500,000,
whether such Indebtedness now exists or shall hereinafter be
created, and such accelerated payment entitles the holder thereof
to immediate payment of such Indebtedness which is due and owing
and such Indebtedness has not been discharged in full or such
acceleration has not been stayed, rescinded or annulled within
fifteen (15) Business Days of such acceleration; or
(e)
A judgment or
judgments for the payment of money shall be rendered against the
Company for an amount in excess of $500,000 in the aggregate (net
of any applicable insurance coverage) for all such judgments that
shall remain unpaid for a period of sixty (60) consecutive days or
more after its entry or issue or that shall not be discharged,
released, dismissed, stayed or bonded (due to an appeal or
otherwise) within the sixty (60) consecutive day period after its
entry or issue; or
(f)
the Company shall
(i) apply for or consent to the appointment of, or the taking of
possession by, a receiver, custodian, trustee or liquidator of
itself or of all or a substantial part of its property or assets,
(ii) make a general assignment for the benefit of its creditors,
(iii) commence a voluntary case under the Federal Bankruptcy Code,
as amended (the “
Bankruptcy Code
”) or
under the comparable laws of any jurisdiction (foreign or
domestic), (iv) file a petition seeking to take advantage of any
bankruptcy, insolvency, moratorium, reorganization or other similar
law affecting the enforcement of creditors’ rights generally,
or (v) acquiesce in writing to any petition filed against it in an
involuntary case under the Bankruptcy Code or under the comparable
laws of any jurisdiction (foreign or domestic); or
(g)
a proceeding or
case shall be commenced in respect of the Company without its
application or consent, in any court of competent jurisdiction,
seeking (i) the liquidation, reorganization, moratorium,
dissolution, winding up, or composition or readjustment of its
debts, (ii) the appointment of a trustee, receiver, custodian,
liquidator or the like of it or of all or any substantial part of
its assets or (iii) similar relief in respect of it under any law
providing for the relief of debtors, and such proceeding or case
described in clause (i), (ii) or (iii) shall continue undismissed,
or unstayed and in effect, for a period of forty-five (45)
consecutive days or any order for relief shall be entered in an
involuntary case under the Bankruptcy Code or under the comparable
laws of any jurisdiction (foreign or domestic) against the Company
or any of its Subsidiaries and shall continue undismissed, or
unstayed and in effect for a period of forty-five (45) consecutive
days.
9.
Remedies
Upon An Event of Default
. If an Event of Default shall have
occurred and shall be continuing, the Payee of this Note may at any
time at its option, (a) declare, by providing the Company with not
less than ten (10) Business Days’ prior written notice, the
entire unpaid principal balance of this Note together with all
interest accrued and unpaid hereon, due and payable, and upon the
Company’s receipt of such notice, the same shall be
accelerated and so due and payable;
provided
,
however
, that upon the
occurrence of an Event of Default described in (i) Sections 8(f)
and (g), without presentment, demand, protest, or notice, all of
which are hereby expressly unconditionally and irrevocably waived
by the Company, the outstanding principal balance and accrued and
unpaid interest hereunder shall be immediately due and payable, and
(ii) Sections 8(a) through (e), the Payee may exercise or otherwise
enforce any one or more of the Payee’s rights, powers,
privileges, remedies and interests under this Note or applicable
law. No course of delay on the part of the Payee shall operate as a
waiver thereof or otherwise prejudice the right of the Payee. No
remedy conferred hereby shall be exclusive of any other remedy
referred to herein or now or hereafter available at law, in equity,
by statute or otherwise.
10.
Rights and Remedies.
No course
of delay on the part of the Payee shall operate as a waiver thereof
or otherwise prejudice the right of the Payee. No remedy conferred
hereby shall be exclusive of any other remedy referred to herein or
now or hereafter available at law, in equity, by statute or
otherwise. Notwithstanding anything to the contrary contained in
this Note, Payee agrees that its rights and remedies hereunder are
limited to receipt of cash or securities of the Company in the
amounts described herein.
11.
Replacement
. Upon receipt of a
duly executed and notarized written statement from the Payee with
respect to the loss, theft or destruction of this Note (or any
replacement hereof), and without requiring an indemnity bond or
other security, or, in the case of a mutilation of this Note, upon
surrender and cancellation of such Note, the Company shall issue a
new Note, of like tenor and amount, in lieu of such lost, stolen,
destroyed or mutilated Note.
12.
Parties in Interest;
Transferability
. This Note shall be binding upon the Company
and its successors and assigns and the terms hereof shall inure to
the benefit of the Payee and its successors and permitted assigns.
This Note may not be transferred or sold, pledged, hypothecated or
otherwise granted as security by the Payee without the prior
written consent of the Company, which consent will not be
unreasonably withheld.
13.
Amendments
. This Note may not
be modified or amended in any manner except in writing executed by
the Company and the holders holding a majority of the then
outstanding Principal Balance of the Notes issued pursuant to the
Purchase Agreement
14.
Notices
. Any notice, demand,
request, waiver or other communication required or permitted to be
given hereunder shall be in writing and shall be effective (a) on
the date of transmission upon hand delivery or by delivery via
telecopy, facsimile or email at the address, email address or
number designated below (if delivered on a Business Day during
normal business hours where such notice is to be received), or the
first Business Day following such delivery (if delivered other than
on a Business Day during normal business hours where such notice is
to be received) or (b) on the second Business Day following the
date of mailing by express courier service, fully prepaid,
addressed to such address, or upon actual receipt of such mailing,
whichever shall first occur.
Address of the
Payee:
[_________]
[_________]
[_________]
Attention:
[_________]
Tel.
No.: [_________]
Fax
No.: [_________]
Email:
[_________]
Address of the
Company:
MetaStat,
Inc.
27
Drydock Ave., 2
nd
Floor
Boston,
MA 02110
Attention: Chief
Executive Officer
Tel.
No.: (617) 531-6500
Fax
No.: (617) 482-3337
Email:
dhamilton@metastat.com
and
dschneiderman@metastat.com
15.
Governing Law
. This Note shall
be governed by and construed in accordance with the internal laws
of the State of New York, without giving effect to the choice of
law provisions. This Note shall not be interpreted or construed
with any presumption against the party causing this Note to be
drafted.
16.
Headings
. Article and section
headings in this Note are included herein for purposes of
convenience of reference only and shall not constitute a part of
this Note for any other purpose.
17.
Remedies, Characterizations, Other
Obligations, Breaches and Injunctive Relief
. The remedies
provided in this Note shall be cumulative and in addition to all
other remedies available under this Note, at law or in equity
(including, without limitation, a decree of specific performance
and/or other injunctive relief), no remedy contained herein shall
be deemed a waiver of compliance with the provisions giving rise to
such remedy and nothing herein shall limit a Payee’s right to
pursue actual damages for any failure by the Company to comply with
the terms of this Note. The Company acknowledges that a breach by
it of its obligations hereunder will cause irreparable and material
harm to the Payee and that the remedy at law for any such breach
may be inadequate. Therefore, the Company agrees that, in the event
of any such breach or threatened breach, the Payee shall be
entitled, in addition to all other available rights and remedies,
at law or in equity, to seek and obtain such equitable relief,
including but not limited to an injunction restraining any such
breach or threatened breach, without the necessity of showing
economic loss and without any bond or other security being
required.
18.
Failure or Delay Not Waiver
. No
failure or delay on the part of the Payee in the exercise of any
power, right or privilege hereunder shall operate as a waiver
thereof, nor shall any single or partial exercise of any such
power, right or privilege preclude other or further exercise
thereof or of any other right, power or privilege.
19.
Enforcement Expenses
. The
Company agrees to pay all reasonable costs and expenses of
enforcement of this Note, including, without limitation, reasonable
attorneys’ fees and expenses.
20.
Binding Effect
. The obligations
of the Company and the Payee set forth herein shall be binding upon
the successors and permitted assigns of each such
party.
21.
Compliance with Securities
Laws
. The Payee acknowledges and agrees that this Note is
being acquired solely for the Payee’s own account and not as
a nominee for any other party, and for investment purposes only and
not with a view to the resale or distribution of any part thereof,
and that the Payee shall not offer, sell or otherwise dispose of
this Note other than in compliance with applicable federal and
state laws. The Payee understands that this Note constitutes
“restricted securities” under applicable federal and
state securities laws and that such securities have not been, and
will not be, registered under the Securities Act of 1933, as
amended (the “
Securities Act
”). The
Payee represents and warrants to the Company that the Payee is an
“accredited investor” as such term is defined in Rule
501 of Regulation D promulgated under the Securities Act. This Note
and any Note issued in substitution or replacement therefore shall
be stamped or imprinted with a legend in substantially the
following form:
“THESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE
SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE
DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER
APPLICABLE STATE SECURITIES LAWS OR UNLESS METASTAT, INC. SHALL
HAVE RECEIVED AN OPINION OF COUNSEL THAT THE REGISTRATION OF SUCH
SECURITIES UNDER THE SECURITIES ACT AND UNDER THE PROVISIONS OF
APPLICABLE STATE SECURITIES LAWS IS NOT
REQUIRED.”
22.
Severability
. The provisions of
this Note are severable, and if any provision shall be held invalid
or unenforceable in whole or in part in any jurisdiction, then such
invalidity or unenforceability shall not in any manner affect such
provision in any other jurisdiction or any other provision of this
Note in any jurisdiction.
23.
Consent to Jurisdiction
. Each
of the Company and the Payee (i) hereby irrevocably submits to the
jurisdiction of the United States District Court sitting in the
Southern District of New York and the courts of the State of New
York located in New York county for the purposes of any suit,
action or proceeding arising out of or relating to this Note and
(ii) hereby waives, and agrees not to assert in any such suit,
action or proceeding, any claim that it is not personally subject
to the jurisdiction of such court, that the suit, action or
proceeding is brought in an inconvenient forum or that the venue of
the suit, action or proceeding is improper. Each of the Company and
the Payee consents to process being served in any such suit, action
or proceeding by mailing a copy thereof to such party at the
address set forth in 14 hereof and agrees that such service shall
constitute good and sufficient service of process and notice
thereof. Nothing in this Section 23 shall affect or limit any right
to serve process in any other manner permitted by applicable
law.
24.
Waivers
. Except as otherwise
specifically provided herein, the Company hereby waives
presentment, demand, notice of nonpayment, protest and all other
demands and notices in connection with the delivery, acceptance,
performance and enforcement of this Note, and does hereby consent
to any number of renewals or extensions of the time for payment
hereof and agrees that any such renewals or extensions may be made
without notice and without affecting its liability herein, AND DOES
HEREBY WAIVE TRIAL BY JURY. No delay or omission on the part of the
Payee in exercising its rights under this Note, or course of
conduct relating hereto, shall operate as a waiver of such rights
or any other right of the Payee, nor shall any waiver by the Payee
of any such right or rights on any one occasion be deemed a waiver
of the same right or rights on any future occasion.
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
IN WITNESS WHEREOF,
the Company has
executed and delivered this Note as of the date first written
above.
METASTAT,
INC.
By:
Name:
Title:
Exhibit 4.2
THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE
SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE
DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER
APPLICABLE STATE SECURITIES LAWS OR UNLESS METASTAT, INC. SHALL
HAVE RECEIVED AN OPINION OF COUNSEL THAT THE REGISTRATION OF SUCH
SECURITIES UNDER THE SECURITIES ACT AND UNDER THE PROVISIONS OF
APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED.
METASTAT, INC.
Junior Non-Convertible Promissory Bridge Note
U.S.
$[________]
No.:
[_______]
|
Issuance
Date: [_____], 2018
Maturity
Date: [Six (6) Months Following the Issuance Date]
|
FOR VALUE RECEIVED
, MetaStat, Inc., a
Nevada corporation (the “
Company
”), hereby
promises to pay to the order of [___________] or any permitted
holder (the “
Payee
”) of this junior
non-convertible promissory bridge note (this “
Note
”), at the principal
office of the Payee set forth herein, or at such other place as the
Payee may designate in writing to the Company, the principal sum of
[___________] Dollars ($[_____]), with interest on the unpaid
principal balance hereof at a rate equal to ten percent (10%) per
annum commencing effective as of the Issuance Date (the
“
Commencement
Date
”), in such currency of the United States of
America as at the time shall be legal tender for the payment of
public and private debts and in immediately available funds, as
provided in this Note. This Note has been entered into pursuant to
the terms of a note purchase agreement (the “
Purchase Agreement
”)
dated as of [_____], 2018 by and among the Company and the
purchasers signatory thereto. Unless otherwise separately defined
herein, each capitalized term used in this Note shall have the same
meaning as set forth in the Purchase Agreement.
1.
Principal, Interest and
Prepayment
.
(a)
The Company shall
repay the entire principal balance plus accrued and unpaid interest
thereon (the “
Outstanding Balance
”)
then outstanding under this Note no later than [six (6) months
following the Issuance Date] (the “
Maturity
Date
”).
(b)
Interest on the
outstanding principal balance of this Note shall accrue at a rate
of ten percent (10%) per annum commencing on the Commencement Date,
which interest shall be computed on the basis of the actual number
of days elapsed and a year of three hundred and sixty-five (365)
days. Furthermore, upon the occurrence of an Event of Default (as
defined below), then to the extent permitted by applicable law, the
Company will pay interest to the Payee on the then outstanding
principal balance of the Note from the date of the Event of Default
until this Note is paid in full at the rate of twelve percent (12%)
per annum.
(c)
The Company may not
prepay this Note, either in whole or in part, absent the
Payee’s prior written consent.
2.
Automatic Exchange of Outstanding
Balance upon Qualified Offering
. Subject to the terms and
conditions of this Section 2 and provided this Note remains
outstanding, this Note shall automatically exchange at the
Outstanding Balance (the “
Automatic Exchange
”),
without any action on the part of the Payee, into such number of
fully paid and non-assessable securities (e.g. shares and warrants)
to be issued in the Qualified Offering (as defined below). With
respect to the Automatic Conversion, the Company and/or the
Company’s investment banker(s) shall communicate and provide
notice of the timing, pricing and closing of the Qualified Offering
to the Payee in the same manner as all other investors in the
Qualified Offering. The Payee shall be deemed to be a purchaser in
the Qualified Offering and shall be granted all rights afforded to
an investor in the Qualified Offering and shall enter into such
reasonable definitive documentation with respect to the Qualified
Offering. For purposes of this Note, “
Qualified Offering
” shall
mean one or a series of offerings of equity or equity-linked
securities following the date of this Note, resulting in aggregate
gross proceeds of at least $6,628,927 to the Company, including the
Automatic Exchange of the Notes into the Qualified
Offering.
3.
Rank
. This Note shall rank
junior with respect to payment to the senior non-convertible
promissory bridge notes issued pursuant to the Purchase Agreement
and senior to all future indebtedness of the Company and to the
Company’s issued and outstanding equity securities, except as
otherwise required by applicable law.
4.
Additional Indebtedness
. The
Company shall not, without first obtaining the consent of from the
Payee (which consent will not be unreasonably withheld), incur any
new Indebtedness (indebtedness of the Company which does not exist
as of the date of this Note) while this Note is outstanding;
provided
,
however
, that the
consent of the Payee will not be required with respect to Permitted
Indebtedness.
5.
Prohibition on Liens
. So long
as this Note is outstanding, the Company shall not create or impose
any material Lien of the Company or any of its Subsidiaries
pursuant to the terms of any agreement or instrument to which any
of them is a party or by which any of them may be bound or to which
any of their property or any of them is subject, except for
Permitted Liens. Failure to comply with the terms of this Section 5
shall be deemed an Event of Default pursuant to Section 8 of this
Note.
6.
Non-Business Days
. Whenever any
payment to be made shall be due on a Saturday, Sunday or a public
holiday under the laws of the State of New York, such payment may
be due on the next succeeding Business Day and such next succeeding
day shall be included in the calculation of the amount of accrued
interest payable on such date.
7.
Representations and Warranties of the
Company
. The Company represents and warrants to the Payee as
follows:
(a)
The Company has
been incorporated and is validly existing and in good standing
under the laws of the State of Nevada, with full corporate power
and authority to own, lease and operate its properties and to
conduct its business as currently conducted.
(b)
This Note has been
duly authorized, validly executed and delivered on behalf of the
Company and is a valid and binding obligation of the Company
enforceable against the Company in accordance with its terms,
subject to limitations on enforcement by general principles of
equity and by bankruptcy or other laws affecting the enforcement of
creditors’ rights generally.
(c)
The execution,
delivery and performance of this Note will not: (i) conflict with
or result in a material breach of or a default under any of the
terms or provisions of, (A) the Company’s articles of
incorporation or by-laws, or (B) any material provision of any
indenture, mortgage, deed of trust or other material agreement or
instrument to which the Company is a party or by which it or any of
its material properties or assets is bound; (ii) result in a
violation of any material provision of any law, statute, rule,
regulation, or any existing applicable decree, judgment or order by
any court, Federal or state regulatory body, administrative agency,
or other governmental body having jurisdiction over the Company, or
any of its material properties or assets; or (iii) result in the
creation or imposition of any material lien or encumbrance upon any
material property or assets of the Company pursuant to the terms of
any agreement or instrument to which the Company is a party or may
be bound or to which the Company or any of its property is
subject.
(d)
No consent,
approval or authorization of or designation, declaration or filing
with any governmental authority on the part of the Company is
required in connection with the valid execution and delivery of
this Note.
8.
Events of Default
. The
occurrence of any of the following events shall be an
“
Event of
Default
” under this Note:
(a)
the Company shall
fail to make the payment of any principal amount outstanding for a
period of ten (10) Business Days after the date such payment shall
become due and payable hereunder; or
(b)
the Company shall
fail to make the payment of any accrued and unpaid interest for a
period of ten (10) Business Days after the date such interest shall
become due and payable hereunder; or
(c)
any material breach
by the Company of any representations or warranties made by the
Company herein; or
(d)
the holder of any
Indebtedness of the Company shall accelerate any payment of any
amount or amounts of principal or interest on any such Indebtedness
(other than with respect to this Note and notes of like tenor)
prior to its stated maturity or payment date, the aggregate
principal amount of which Indebtedness is in excess of $500,000,
whether such Indebtedness now exists or shall hereinafter be
created, and such accelerated payment entitles the holder thereof
to immediate payment of such Indebtedness which is due and owing
and such Indebtedness has not been discharged in full or such
acceleration has not been stayed, rescinded or annulled within
fifteen (15) Business Days of such acceleration; or
(e)
A judgment or
judgments for the payment of money shall be rendered against the
Company for an amount in excess of $500,000 in the aggregate (net
of any applicable insurance coverage) for all such judgments that
shall remain unpaid for a period of sixty (60) consecutive days or
more after its entry or issue or that shall not be discharged,
released, dismissed, stayed or bonded (due to an appeal or
otherwise) within the sixty (60) consecutive day period after its
entry or issue; or
(f)
the Company shall
(i) apply for or consent to the appointment of, or the taking of
possession by, a receiver, custodian, trustee or liquidator of
itself or of all or a substantial part of its property or assets,
(ii) make a general assignment for the benefit of its creditors,
(iii) commence a voluntary case under the Federal Bankruptcy Code,
as amended (the “
Bankruptcy Code
”) or
under the comparable laws of any jurisdiction (foreign or
domestic), (iv) file a petition seeking to take advantage of any
bankruptcy, insolvency, moratorium, reorganization or other similar
law affecting the enforcement of creditors’ rights generally,
or (v) acquiesce in writing to any petition filed against it in an
involuntary case under the Bankruptcy Code or under the comparable
laws of any jurisdiction (foreign or domestic); or
(g)
a proceeding or
case shall be commenced in respect of the Company without its
application or consent, in any court of competent jurisdiction,
seeking (i) the liquidation, reorganization, moratorium,
dissolution, winding up, or composition or readjustment of its
debts, (ii) the appointment of a trustee, receiver, custodian,
liquidator or the like of it or of all or any substantial part of
its assets or (iii) similar relief in respect of it under any law
providing for the relief of debtors, and such proceeding or case
described in clause (i), (ii) or (iii) shall continue undismissed,
or unstayed and in effect, for a period of forty-five (45)
consecutive days or any order for relief shall be entered in an
involuntary case under the Bankruptcy Code or under the comparable
laws of any jurisdiction (foreign or domestic) against the Company
or any of its Subsidiaries and shall continue undismissed, or
unstayed and in effect for a period of forty-five (45) consecutive
days.
9.
Remedies
Upon An Event of Default
. If an Event of Default shall have
occurred and shall be continuing, the Payee of this Note may at any
time at its option, (a) declare, by providing the Company with not
less than ten (10) Business Days’ prior written notice, the
entire unpaid principal balance of this Note together with all
interest accrued and unpaid hereon, due and payable, and upon the
Company’s receipt of such notice, the same shall be
accelerated and so due and payable;
provided
,
however
, that upon the
occurrence of an Event of Default described in (i) Sections 8(f)
and (g), without presentment, demand, protest, or notice, all of
which are hereby expressly unconditionally and irrevocably waived
by the Company, the outstanding principal balance and accrued and
unpaid interest hereunder shall be immediately due and payable, and
(ii) Sections 8(a) through (e), the Payee may exercise or otherwise
enforce any one or more of the Payee’s rights, powers,
privileges, remedies and interests under this Note or applicable
law. No course of delay on the part of the Payee shall operate as a
waiver thereof or otherwise prejudice the right of the Payee. No
remedy conferred hereby shall be exclusive of any other remedy
referred to herein or now or hereafter available at law, in equity,
by statute or otherwise.
10.
Rights and Remedies.
No course
of delay on the part of the Payee shall operate as a waiver thereof
or otherwise prejudice the right of the Payee. No remedy conferred
hereby shall be exclusive of any other remedy referred to herein or
now or hereafter available at law, in equity, by statute or
otherwise. Notwithstanding anything to the contrary contained in
this Note, Payee agrees that its rights and remedies hereunder are
limited to receipt of cash or securities of the Company in the
amounts described herein.
11.
Replacement
. Upon receipt of a
duly executed and notarized written statement from the Payee with
respect to the loss, theft or destruction of this Note (or any
replacement hereof), and without requiring an indemnity bond or
other security, or, in the case of a mutilation of this Note, upon
surrender and cancellation of such Note, the Company shall issue a
new Note, of like tenor and amount, in lieu of such lost, stolen,
destroyed or mutilated Note.
12.
Parties in Interest;
Transferability
. This Note shall be binding upon the Company
and its successors and assigns and the terms hereof shall inure to
the benefit of the Payee and its successors and permitted assigns.
This Note may not be transferred or sold, pledged, hypothecated or
otherwise granted as security by the Payee without the prior
written consent of the Company, which consent will not be
unreasonably withheld.
13.
Amendments
. This Note may not
be modified or amended in any manner except in writing executed by
the Company and the holders holding a majority of the then
outstanding Principal Balance of the Notes issued pursuant to the
Purchase Agreement
14.
Notices
. Any notice, demand,
request, waiver or other communication required or permitted to be
given hereunder shall be in writing and shall be effective (a) on
the date of transmission upon hand delivery or by delivery via
telecopy, facsimile or email at the address, email address or
number designated below (if delivered on a Business Day during
normal business hours where such notice is to be received), or the
first Business Day following such delivery (if delivered other than
on a Business Day during normal business hours where such notice is
to be received) or (b) on the second Business Day following the
date of mailing by express courier service, fully prepaid,
addressed to such address, or upon actual receipt of such mailing,
whichever shall first occur.
Address of the
Payee:
[_________]
[_________]
[_________]
Attention:
[_________]
Tel.
No.: [_________]
Fax
No.: [_________] Email: [_________]
Address of the
Company:
MetaStat,
Inc.
27
Drydock Ave., 2
nd
Floor
Boston,
MA 02110
Attention: Chief
Executive Officer
Tel.
No.: (617) 531-6500
Fax
No.: (617) 482-3337
Email:
dhamilton@metastat.com
and
dschneiderman@metastat.com
15.
Governing Law
. This Note shall
be governed by and construed in accordance with the internal laws
of the State of New York, without giving effect to the choice of
law provisions. This Note shall not be interpreted or construed
with any presumption against the party causing this Note to be
drafted.
16.
Headings
. Article and section
headings in this Note are included herein for purposes of
convenience of reference only and shall not constitute a part of
this Note for any other purpose.
17.
Remedies, Characterizations, Other
Obligations, Breaches and Injunctive Relief
. The remedies
provided in this Note shall be cumulative and in addition to all
other remedies available under this Note, at law or in equity
(including, without limitation, a decree of specific performance
and/or other injunctive relief), no remedy contained herein shall
be deemed a waiver of compliance with the provisions giving rise to
such remedy and nothing herein shall limit a Payee’s right to
pursue actual damages for any failure by the Company to comply with
the terms of this Note. The Company acknowledges that a breach by
it of its obligations hereunder will cause irreparable and material
harm to the Payee and that the remedy at law for any such breach
may be inadequate. Therefore, the Company agrees that, in the event
of any such breach or threatened breach, the Payee shall be
entitled, in addition to all other available rights and remedies,
at law or in equity, to seek and obtain such equitable relief,
including but not limited to an injunction restraining any such
breach or threatened breach, without the necessity of showing
economic loss and without any bond or other security being
required.
18.
Failure or Delay Not Waiver
. No
failure or delay on the part of the Payee in the exercise of any
power, right or privilege hereunder shall operate as a waiver
thereof, nor shall any single or partial exercise of any such
power, right or privilege preclude other or further exercise
thereof or of any other right, power or privilege.
19.
Enforcement Expenses
. The
Company agrees to pay all reasonable costs and expenses of
enforcement of this Note, including, without limitation, reasonable
attorneys’ fees and expenses.
20.
Binding Effect
. The obligations
of the Company and the Payee set forth herein shall be binding upon
the successors and permitted assigns of each such
party.
21.
Compliance with Securities
Laws
. The Payee acknowledges and agrees that this Note is
being acquired solely for the Payee’s own account and not as
a nominee for any other party, and for investment purposes only and
not with a view to the resale or distribution of any part thereof,
and that the Payee shall not offer, sell or otherwise dispose of
this Note other than in compliance with applicable federal and
state laws. The Payee understands that this Note constitutes
“restricted securities” under applicable federal and
state securities laws and that such securities have not been, and
will not be, registered under the Securities Act of 1933, as
amended (the “
Securities Act
”). The
Payee represents and warrants to the Company that the Payee is an
“accredited investor” as such term is defined in Rule
501 of Regulation D promulgated under the Securities Act. This Note
and any Note issued in substitution or replacement therefore shall
be stamped or imprinted with a legend in substantially the
following form:
“THESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE
SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE
DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER
APPLICABLE STATE SECURITIES LAWS OR UNLESS METASTAT, INC. SHALL
HAVE RECEIVED AN OPINION OF COUNSEL THAT THE REGISTRATION OF SUCH
SECURITIES UNDER THE SECURITIES ACT AND UNDER THE PROVISIONS OF
APPLICABLE STATE SECURITIES LAWS IS NOT
REQUIRED.”
22.
Severability
. The provisions of
this Note are severable, and if any provision shall be held invalid
or unenforceable in whole or in part in any jurisdiction, then such
invalidity or unenforceability shall not in any manner affect such
provision in any other jurisdiction or any other provision of this
Note in any jurisdiction.
23.
Consent to Jurisdiction
. Each
of the Company and the Payee (i) hereby irrevocably submits to the
jurisdiction of the United States District Court sitting in the
Southern District of New York and the courts of the State of New
York located in New York county for the purposes of any suit,
action or proceeding arising out of or relating to this Note and
(ii) hereby waives, and agrees not to assert in any such suit,
action or proceeding, any claim that it is not personally subject
to the jurisdiction of such court, that the suit, action or
proceeding is brought in an inconvenient forum or that the venue of
the suit, action or proceeding is improper. Each of the Company and
the Payee consents to process being served in any such suit, action
or proceeding by mailing a copy thereof to such party at the
address set forth in 14 hereof and agrees that such service shall
constitute good and sufficient service of process and notice
thereof. Nothing in this Section 23 shall affect or limit any right
to serve process in any other manner permitted by applicable
law.
24.
Waivers
. Except as otherwise
specifically provided herein, the Company hereby waives
presentment, demand, notice of nonpayment, protest and all other
demands and notices in connection with the delivery, acceptance,
performance and enforcement of this Note, and does hereby consent
to any number of renewals or extensions of the time for payment
hereof and agrees that any such renewals or extensions may be made
without notice and without affecting its liability herein, AND DOES
HEREBY WAIVE TRIAL BY JURY. No delay or omission on the part of the
Payee in exercising its rights under this Note, or course of
conduct relating hereto, shall operate as a waiver of such rights
or any other right of the Payee, nor shall any waiver by the Payee
of any such right or rights on any one occasion be deemed a waiver
of the same right or rights on any future occasion.
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
IN WITNESS WHEREOF,
the Company has
executed and delivered this Note as of the date first written
above.
METASTAT,
INC.
By:
Name:
Title:
Exhibit
4.3
NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS
EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE
COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE
UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF
1933, AS AMENDED (THE “SECURITIES ACT”), AND,
ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN
EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR
PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT
SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND
IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY
A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE
SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE
COMPANY.
COMMON STOCK PURCHASE WARRANT
METASTAT, INC.
Warrant Shares:
[_____]
Warrant
No. W- [_____]
|
Initial Exercise
Date: [_____], 2018
|
THIS
COMMON STOCK PURCHASE WARRANT (the “
Warrant
”) certifies that,
for value received, [_____] or its assigns (the “
Holder
”) is entitled,
upon the terms and subject to the limitations on exercise and the
conditions hereinafter set forth, at any time on or after the date
hereof (the “
Initial
Exercise Date
”) and on or prior to the close of
business on the five-year anniversary of the Initial Exercise Date
(the “
Termination
Date
”) but not thereafter, to subscribe for and
purchase from MetaStat, Inc., a Nevada corporation (the
“
Company
”), up to [_____]
shares (as subject to adjustment hereunder, the “
Warrant Shares
”) of
Common Stock. The purchase price of one share of Common Stock under
this Warrant shall be equal to the Exercise Price, as defined in
Section 2(c). This Warrant is being issued in accordance with the
Note Purchase Agreement (the “
Purchase Agreement
”),
dated [_____], 2018, among the Company and the purchasers signatory
thereto.
Section
1
.
Definitions
.
Capitalized terms used and not otherwise defined herein shall have
the meanings set forth in the Purchase Agreement. The following
definitions shall apply for purposes of this Warrant:
a)
“
Business Day
” means any
day except Saturday, Sunday, any day which is a federal legal
holiday in the United States or any day on which banking
institutions in the State of New York are authorized or required by
law or other governmental action to close.
b)
“
Trading Day
” means a day
on which the principal Trading Market is open for trading;
provided, that in the event that the Common Stock is not listed or
quoted on a Trading Market, then Trading Day shall mean a Business
Day.
c)
“
Trading Market
” means
whichever of the following markets or exchanges on which the Common
Stock is listed or quoted for trading on the date in question: the
New York Stock Exchange, the NYSE American, the NASDAQ Global
Select Market, the NASDAQ Global Market, the NASDAQ Capital Market,
the OTC Bulletin Board or any tier of the OTC Markets Group, Inc.
(or any successors to any of the foregoing).
Section
2
.
Exercise
.
a)
Exercise
of Warrant
. Exercise of the purchase rights represented by
this Warrant may be made, in whole or in part, at any time or times
on or after the Initial Exercise Date and on or before the
Termination Date by delivery to the Company (or such other office
or agency of the Company as it may designate by notice in writing
to the registered Holder at the address of the Holder appearing on
the books of the Company) of a duly executed facsimile copy (or
email attachment) of the Notice of Exercise in the form annexed
hereto. Within the earlier of (i) three (3) Trading Days and (ii)
the number of Trading Days comprising the Standard Settlement
Period (as defined in Section 2(d)(i) herein) following the date of
exercise as aforesaid, the Holder shall deliver the aggregate
Exercise Price for the shares specified in the applicable Notice of
Exercise by wire transfer or cashier’s check drawn on a
United States bank unless the cashless exercise procedure specified
in Section 2(c) below is specified in the applicable Notice of
Exercise. No ink-original Notice of Exercise shall be
required, nor shall any medallion guarantee (or other type of
guarantee or notarization) of any Notice of Exercise form be
required. Notwithstanding anything herein to the contrary, the
Holder shall not be required to physically surrender this Warrant
to the Company until the Holder has purchased all of the Warrant
Shares available hereunder and the Warrant has been exercised in
full, in which case, the Holder shall surrender this Warrant to the
Company for cancellation within five (5) Trading Days of the date
the final Notice of Exercise is delivered to the Company. Partial
exercises of this Warrant resulting in purchases of a portion of
the total number of Warrant Shares available hereunder shall have
the effect of lowering the outstanding number of Warrant Shares
purchasable hereunder in an amount equal to the applicable number
of Warrant Shares purchased. The Holder and the Company shall
maintain records showing the number of Warrant Shares purchased and
the date of such purchases. The Company shall deliver any objection
to any Notice of Exercise within two (2) Business Days of receipt
of such notice. The Holder and any assignee, by acceptance of this
Warrant, acknowledge and agree that, by reason of the provisions of
this paragraph, following the purchase of a portion of the Warrant
Shares hereunder, the number of Warrant Shares available for
purchase hereunder at any given time may be less than the amount
stated on the face hereof.
b)
Cashless Exercise
.
Notwithstanding any provision herein to the contrary, commencing
six (6) months from the Initial Exercise Date if the Per Share
Market Value (as defined below) of one share of Common Stock is
greater than the Exercise Price (at the date of calculation as set
forth below) and there is not an effective registration statement
under the Securities Act providing for the resale of the Warrant
Shares, in lieu of exercising this Warrant by payment of cash, the
Holder may exercise this Warrant by a cashless exercise by
surrender of this Warrant at the principal office of the Company
together with the properly endorsed Notice of Exercise, in which
event the Company shall issue to the Holder a number of shares of
Common Stock computed using the following formula:
X = Y x
(B-A)
Where
X
=
the number of
Warrant Shares to be issued to the Holder.
Y
=
the number of
Warrant Shares purchasable upon exercise of all of the Warrant or,
if only a portion of the Warrant is being exercised, the portion of
the Warrant being exercised.
B
= the
Per Share Market Value of one share of Common Stock.
For
purposes hereof, “
Per Share Market Value
”
means on any particular date, the price determined by the first of
the following clauses that applies: (a) if the Common Stock is then
listed or quoted on a Trading Market, the bid price of the Common
Stock for the time in question (or the nearest preceding date) on
the Trading Market on which the Common Stock is then listed or
quoted as reported by Bloomberg L.P. (based on a Trading Day from
9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)),
(b) if the Common Stock is not then listed or quoted for trading on
a Trading Market and if prices for the Common Stock are then
reported in the “Pink Sheets” published by OTC Markets
Group, Inc. (or a similar organization or agency succeeding to its
functions of reporting prices), the most recent bid price per share
of Common Stock so reported, or (c) in all other cases, the fair
market value of a share of Common Stock as determined by an
independent appraiser selected in good faith by the Holders of a
majority in interest of the Securities issuable pursuant to the
Purchase Agreement
then outstanding and reasonably acceptable to the Company, the fees
and expenses of which shall be paid by the Company.
If
Warrant Shares are issued in such a cashless exercise, the parties
acknowledge and agree that in accordance with Section 3(a)(9) of
the Securities Act, the Warrant Shares shall take on the
characteristics of the Warrants being exercised, and the holding
period of the Warrant Shares being issued may be tacked on to the
holding period of this Warrant. The Company agrees not
to take any position contrary to this Section 2(b).
c)
Exercise Price
. The exercise
price per share of the Common Stock under this Warrant shall be
$2.00
, subject to adjustment
hereunder (the “
Exercise
Price
”).
d)
Mechanics of
Exercise
.
i.
Delivery of Certificates Upon
Exercise
. Warrant Shares purchased hereunder shall be
transmitted by the Transfer Agent to the Holder by crediting the
account of the Holder’s or its designee’s balance
account with The Depository Trust Company through its Deposit or
Withdrawal at Custodian system (“DWAC”) if the Company
is then a participant in such system and either (A) there is an
effective registration statement permitting the issuance of the
Warrant Shares to or resale of the Warrant Shares by the Holder and
the Holder has provided the Company with written representations as
reasonably requested by the Company in connection with such legend
removal or (B) the Warrant Shares are eligible for resale by the
Holder without volume or manner-of-sale limitations pursuant to
Rule 144 and the Holder has provided the Company with written
representations as reasonably requested by the Company in
connection with such legend removal, and otherwise by physical
delivery of a certificate, registered in the Company’s share
register in the name of the Holder or its designee, for the number
of Warrant Shares to which the Holder is entitled pursuant to such
exercise to the address specified by the Holder in the Notice of
Exercise by the date that is the earlier of (i) three (3) Trading
Days and (ii) the number of Trading Days comprising the Standard
Settlement Period after the delivery to the Company of the Notice
of Exercise (such date, the “Warrant Share Delivery
Date”). Upon delivery of the Notice of Exercise, the Holder
shall be deemed for all corporate purposes to have become the
holder of record of the Warrant Shares with respect to which this
Warrant has been exercised, irrespective of the date of delivery of
the Warrant Shares, provided that payment of the aggregate Exercise
Price (other than in the case of a cashless exercise) is received
within the earlier of (i) two Trading Days and (ii) the number of
Trading Days comprising the Standard Settlement Period following
delivery of the Notice of Exercise. The Company agrees to maintain
a transfer agent that is a participant in the FAST program so long
as this Warrant remains outstanding and exercisable. As used
herein, “Standard Settlement Period” means the standard
settlement period, expressed in a number of Trading Days, on the
Company’s primary Trading Market with respect to the Common
Stock as in effect on the date of delivery of the Notice of
Exercise.
ii.
Delivery of New Warrants Upon
Exercise
. If this Warrant shall have been exercised in part,
the Company shall, at the request of a Holder and upon surrender of
this Warrant certificate, at the time of delivery of the Warrant
Shares, deliver to the Holder a new Warrant evidencing the rights
of the Holder to purchase the unpurchased Warrant Shares called for
by this Warrant, which new Warrant shall in all other respects be
identical with this Warrant.
iii.
Rescission
Rights
. If the Company fails to cause the Transfer Agent to
transmit to the Holder a certificate or the certificates
representing the Warrant Shares pursuant to Section 2(d)(i) by the
Warrant Share Delivery Date, then the Holder will have the right to
rescind such exercise.
iv.
Compensation for Buy-In on Failure to
Timely Deliver Certificates Upon Exercise
. In addition to
any other rights available to the Holder, if the Company fails to
cause the Transfer Agent to transmit to the Holder the Warrant
Shares in accordance with the provisions of Section 2(d)(i) above
pursuant to an exercise on or before the Warrant Share Delivery
Date, and if after such date the Holder is required by its broker
to purchase (in an open market transaction or otherwise) or the
Holder’s brokerage firm otherwise purchases, shares of Common
Stock to deliver in satisfaction of a sale by the Holder of the
Warrant Shares which the Holder anticipated receiving upon such
exercise (a “
Buy-In
”), then the
Company shall (A) pay in cash to the Holder the amount, if any, by
which (x) the Holder’s total purchase price (including
brokerage commissions, if any) for the shares of Common Stock so
purchased exceeds (y) the amount obtained by multiplying (1) the
number of Warrant Shares that the Company was required to deliver
to the Holder in connection with the exercise at issue times (2)
the price at which the sell order giving rise to such purchase
obligation was executed, and (B) at the option of the Holder,
either reinstate the portion of the Warrant and equivalent number
of Warrant Shares for which such exercise was not honored (in which
case such exercise shall be deemed rescinded) or deliver to the
Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and
delivery obligations hereunder. For example, if the Holder
purchases Common Stock having a total purchase price of $11,000 to
cover a Buy-In with respect to an attempted exercise of shares of
Common Stock with an aggregate sale price giving rise to such
purchase obligation of $10,000, under clause (A) of the immediately
preceding sentence the Company shall be required to pay the Holder
$1,000. The Holder shall provide the Company written notice
indicating the amounts payable to the Holder in respect of the
Buy-In and, upon request of the Company, evidence of the amount of
such loss. Nothing herein shall limit a Holder’s right to
pursue any other remedies available to it hereunder, at law or in
equity including, without limitation, a decree of specific
performance and/or injunctive relief with respect to the
Company’s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms
hereof.
v.
No Fractional Shares or Scrip
.
No fractional shares or scrip representing fractional shares shall
be issued upon the exercise of this Warrant. As to any fraction of
a share which the Holder would otherwise be entitled to purchase
upon such exercise, the Company shall, at its election, either pay
a cash adjustment in respect of such final fraction in an amount
equal to such fraction multiplied by the Exercise Price or round up
to the next whole share.
vi.
Charges, Taxes and Expenses
.
Issuance of Warrant Shares shall be made without charge to the
Holder for any issue or transfer tax or other incidental expense in
respect of the issuance of such Warrant Shares, all of which taxes
and expenses shall be paid by the Company, and such Warrant Shares
shall be issued in the name of the Holder or in such name or names
as may be directed by the Holder; provided, however, that in the
event that Warrant Shares are to be issued in a name other than the
name of the Holder, this Warrant when surrendered for exercise
shall be accompanied by the Assignment Form attached hereto duly
executed by the Holder and the Company may require, as a condition
thereto, the payment of a sum sufficient to reimburse it for any
transfer tax incidental thereto. The Company shall pay all Transfer
Agent fees required for same-day processing of any Notice of
Exercise and all fees to the Depository Trust Company (or another
established clearing corporation performing similar functions)
required for same-day electronic delivery of the Warrant
Shares.
vii.
Closing
of Books
. The Company will not close its stockholder books
or records in any manner which prevents the timely exercise of this
Warrant, pursuant to the terms hereof.
e)
Holder’s
Exercise Limitations
. The Company shall not effect any
exercise of this Warrant, and a Holder shall not have the right to
exercise any portion of this Warrant, pursuant to Section 2 or
otherwise, to the extent that after giving effect to such issuance
after exercise as set forth on the applicable Notice of Exercise,
the Holder (together with the Holder’s Affiliates, and any
other Persons acting as a group together with the Holder or any of
the Holder’s Affiliates) (such Persons, “Attribution
Parties”), would beneficially own in excess of the Beneficial
Ownership Limitation (as defined below). For purposes of the
foregoing sentence, the number of shares of Common Stock
beneficially owned by the Holder and its Affiliates and Attribution
Parties shall include the number of shares of Common Stock issuable
upon exercise of this Warrant with respect to which such
determination is being made, but shall exclude the number of shares
of Common Stock which would be issuable upon (i) exercise of the
remaining, nonexercised portion of this Warrant beneficially owned
by the Holder or any of its Affiliates (or Attribution Parties) and
(ii) exercise or conversion of the unexercised or nonconverted
portion of any other securities of the Company (including, without
limitation, any other Common Stock Equivalents) subject to a
limitation on conversion or exercise analogous to the limitation
contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties. Except as set forth in the
preceding sentence, for purposes of this Section 2(e), beneficial
ownership shall be calculated in accordance with Section 13(d) of
the Exchange Act and the rules and regulations promulgated
thereunder, it being acknowledged by the Holder that the Company is
not representing to the Holder that such calculation is in
compliance with Section 13(d) of the Exchange Act and the Holder is
solely responsible for any schedules required to be filed in
accordance therewith. To the extent that the limitation contained
in this Section 2(e) applies, the determination of whether this
Warrant is exercisable (in relation to other securities owned by
the Holder together with any Affiliates and Attribution Parties)
and of which portion of this Warrant is exercisable shall be in the
sole discretion of the Holder, and the submission of a Notice of
Exercise shall be deemed to be the Holder’s determination of
whether this Warrant is exercisable (in relation to other
securities owned by the Holder together with any Affiliates and
Attribution Parties) and of which portion of this Warrant is
exercisable, in each case subject to the Beneficial Ownership
Limitation, and the Company shall have no obligation to verify or
confirm the accuracy of such determination. In addition, a
determination as to any group status as contemplated above shall be
determined in accordance with Section 13(d) of the Exchange Act and
the rules and regulations promulgated thereunder. For purposes of
this Section 2(e), in determining the number of outstanding shares
of Common Stock, a Holder may rely on the number of outstanding
shares of Common Stock as reflected in (A) the Company’s most
recent periodic or annual report filed with the Commission, as the
case may be, (B) a more recent public announcement by the Company
or (C) a more recent written notice by the Company or the Transfer
Agent setting forth the number of shares of Common Stock
outstanding. Upon the written or oral request of a Holder,
the Company shall within two Trading Days confirm orally and in
writing to the Holder the number of shares of Common Stock then
outstanding. In any case, the number of outstanding shares of
Common Stock shall be determined after giving effect to the
conversion or exercise of securities of the Company, including this
Warrant, by the Holder or its Affiliates or Attribution Parties
since the date as of which such number of outstanding shares of
Common Stock was reported. The “
Beneficial Ownership
Limitation
” shall be 4.99% of the number of shares of
the Common Stock outstanding immediately after giving effect to the
issuance of shares of Common Stock issuable upon exercise of this
Warrant. The Holder, upon notice to the Company, may increase or
decrease the Beneficial Ownership Limitation provisions of this
Section 2(e), provided that the Beneficial Ownership Limitation in
no event exceeds 9.99% of the number of shares of the Common Stock
outstanding immediately after giving effect to the issuance of
shares of Common Stock upon exercise of this Warrant held by the
Holder and the provisions of this Section 2(e) shall continue to
apply. Any such increase in the Beneficial Ownership Limitation
will not be effective until the 61
st
day after such
notice is delivered to the Company. The provisions of this
paragraph shall be construed and implemented in a manner otherwise
than in strict conformity with the terms of this Section 2(e) to
correct this paragraph (or any portion hereof) which may be
defective or inconsistent with the intended Beneficial Ownership
Limitation herein contained or to make changes or supplements
necessary or desirable to properly give effect to such limitation.
The limitations contained in this paragraph shall apply to a
successor holder of this Warrant.
Section
3
.
Certain
Adjustments
.
a)
Adjustments
for Stock Splits, Combinations, Certain Dividends and
Distributions
. If the Company shall, at any time or from
time to time after the Initial Exercise Date, effect a split of the
outstanding Common Stock (or any other subdivision of its shares of
Common Stock into a larger number of shares of Common Stock),
combine the outstanding shares of Common Stock into a smaller
number of shares of Common Stock, or make or issue or set a record
date for the determination of holders of Common Stock entitled to
receive a dividend or other distribution payable in shares of
Common Stock, then, in each event (i) the number of shares of
Common Stock for which this Warrant shall be exercisable
immediately after the occurrence of any such event shall be
adjusted to equal the number of shares of Common Stock that a
record holder of the same number of shares of Common Stock for
which this Warrant is exercisable immediately prior to the
occurrence of such event would own or be entitled to receive after
the happening of such event, and (ii) the Exercise Price then in
effect shall be adjusted to equal (A) the Exercise Price then in
effect multiplied by the number of shares of Common Stock for which
this Warrant is exercisable immediately prior to the adjustment
divided by (B) the number of shares of Common Stock for which this
Warrant is exercisable immediately after such
adjustment.
b)
Adjustment
for Other Dividends and Distributions
. If the Company shall,
at any time or from time to time after the Initial Exercise Date,
make or issue or set a record date for the determination of holders
of Common Stock entitled to receive a dividend or other
distribution payable in (i) cash, (ii) any evidences of
indebtedness, or any other securities of the Company or any
property of any nature whatsoever, other than, in each case, shares
of Common Stock; or (iii) any warrants or other rights to subscribe
for or purchase any evidences of indebtedness, or any other
securities of the Company or any property of any nature whatsoever,
other than, in each case, shares of Common Stock, then, and in each
event, (A) the number of shares of Common Stock for which this
Warrant shall be exercisable shall be adjusted to equal the product
of the number of shares of Common Stock for which this Warrant is
exercisable immediately prior to such adjustment multiplied by a
fraction (1) the numerator of which shall be the last closing bid
price per share of the Common Stock at the date of taking such
record and (2) the denominator of which shall be such last closing
bid price per share of the Common Stock minus the amount allocable
to one share of Common Stock of any such cash so distributable and
of the fair value (as determined in good faith by the Board) of any
and all such evidences of indebtedness, shares of stock, other
securities or property or warrants or other subscription or
purchase rights so distributable, and (B) the Exercise Price then
in effect shall be adjusted to equal (1) the Exercise Price then in
effect multiplied by the number of shares of Common Stock for which
this Warrant is exercisable immediately prior to the adjustment
divided by (2) the number of shares of Common Stock for which this
Warrant is exercisable immediately after such adjustment. A
reclassification of the Common Stock (other than a change in par
value, or from par value to no par value or from no par value to
par value) into shares of Common Stock and shares of any other
class of stock shall be deemed a distribution by the Company to the
holders of its Common Stock of such shares of such other class of
stock within the meaning of this Section 3(b) and, if the
outstanding shares of Common Stock shall be changed into a larger
or smaller number of shares of Common Stock as a part of such
reclassification, such change shall be deemed a subdivision or
combination, as the case may be, of the outstanding shares of
Common Stock within the meaning of Section 3(a).
c)
Adjustments
for Reclassification, Exchange or Substitution
. If the
Common Stock for which this Warrant is exercisable at any time or
from time to time after the Initial Exercise Date shall be changed
to the same or different number of shares of any class or classes
of stock, whether by reclassification, exchange, substitution or
otherwise (other than by way of a stock split or combination of
shares or stock dividends provided for in Section 3(a), Section
3(b), or a reorganization, merger, consolidation, or sale of assets
provided for in Section 3(d)), then, and in each event, an
appropriate revision to the Exercise Price shall be made and
provisions shall be made (by adjustments of the Exercise Price or
otherwise) so that, upon any subsequent exercise of this Warrant,
the Holder shall have the right to receive, in lieu of Common
Stock, the kind and amount of shares of stock and other securities
receivable upon reclassification, exchange, substitution or other
change, by holders of the number of shares of Common Stock for
which this Warrant was exercisable immediately prior to such
reclassification, exchange, substitution or other change, all
subject to further adjustment as provided herein.
d)
Adjustments
for Reorganization, Merger, Consolidation or Sales of
Assets
. If at any time or from time to time after the
Initial Exercise Date there shall be a capital reorganization of
the Company (other than by way of a stock split or combination of
shares or stock dividends or distributions provided for in Section
3(a), and Section 3(b), or a reclassification, exchange or
substitution of shares provided for in Section 3(c)), or a merger
or consolidation of the Company with or into another corporation
where the holders of the Company’s outstanding voting
securities prior to such merger or consolidation do not own over
50% of the outstanding voting securities of the merged or
consolidated entity, immediately after such merger or
consolidation, or the sale of all or substantially all of the
Company’s properties or assets to any other person (an
“
Organic
Change
”), then as a part of such Organic Change an
appropriate revision to the Exercise Price shall be made if
necessary and provision shall be made if necessary (by adjustments
of the Exercise Price or otherwise) so that, upon any subsequent
exercise of this Warrant, the Holder shall have the right to
receive, in lieu of Common Stock, the kind and amount of shares of
stock and other securities or property of the Company or any
successor corporation resulting from the Organic Change. In any
such case, appropriate adjustment shall be made in the application
of the provisions of this Section 3(d) with respect to the rights
of the Holder after the Organic Change to the end that the
provisions of this Section 3(d) (including any adjustment in the
Exercise Price then in effect and the number of shares of stock or
other securities deliverable upon exercise of this Warrant) shall
be applied after that event in as nearly an equivalent manner as
may be practicable.
e)
Calculations
.
All calculations under this Section 3 shall be made to the nearest
cent or the nearest 1/100th of a share, as the case may be. For
purposes of this Section 3, the number of shares of Common Stock
deemed to be issued and outstanding as of a given date shall be the
sum of the number of shares of Common Stock (excluding treasury
shares, if any) issued and outstanding.
i.
Adjustment to Exercise Price
.
Whenever the Exercise Price is adjusted pursuant to any provision
of this Section 3, the Company shall promptly deliver to the Holder
a notice by facsimile or email setting forth the Exercise Price
after such adjustment and any resulting adjustment to the number of
Warrant Shares and setting forth a brief statement of the facts
requiring such adjustment.
ii.
Notice to Allow Exercise by
Holder
. If (A) the Company shall declare a dividend (or any
other distribution in whatever form) on the Common Stock, (B) the
Company shall declare a special nonrecurring cash dividend on or a
redemption of the Common Stock, (C) the Company shall authorize the
granting to all holders of the Common Stock rights or warrants to
subscribe for or purchase any shares of capital stock of any class
or of any rights, (D) the approval of any stockholders of the
Company shall be required in connection with any reclassification
of the Common Stock, any consolidation or merger to which the
Company is a party, any sale or transfer of all or substantially
all of the assets of the Company, or any compulsory share exchange
whereby the Common Stock is converted into other securities, cash
or property, or (E) the Company shall authorize the voluntary or
involuntary dissolution, liquidation or winding up of the affairs
of the Company, then, in each case, the Company shall cause to be
delivered by facsimile or email to the Holder at its last facsimile
number or email address as it shall appear upon the Warrant
Register of the Company, at least 20 calendar days prior to the
applicable record or effective date hereinafter specified, a notice
stating (x) the date on which a record is to be taken for the
purpose of such dividend, distribution, redemption, rights or
warrants, or if a record is not to be taken, the date as of which
the holders of the Common Stock of record to be entitled to such
dividend, distributions, redemption, rights or warrants are to be
determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected
to become effective or close, and the date as of which it is
expected that holders of the Common Stock of record shall be
entitled to exchange their shares of the Common Stock for
securities, cash or other property deliverable upon such
reclassification, consolidation, merger, sale, transfer or share
exchange; provided that the failure to deliver such notice or any
defect therein or in the delivery thereof shall not affect the
validity of the corporate action required to be specified in such
notice. To the extent that any notice provided hereunder
constitutes, or contains, material, non-public information
regarding the Company or any of the Subsidiaries, the Company shall
simultaneously file such notice with the Commission pursuant to a
Current Report on Form 8-K. The Holder shall remain entitled to
exercise this Warrant during the period commencing on the date of
such notice to the effective date of the event triggering such
notice except as may otherwise be expressly set forth
herein.
Section
4
.
Transfer
of Warrant
.
a)
Transferability
. Subject to
compliance with any applicable securities laws, this Warrant and
all rights hereunder (including, without limitation, any
registration rights) are transferable, in whole or in part, upon
surrender of this Warrant at the principal office of the Company or
its designated agent, together with a written assignment of this
Warrant substantially in the form attached hereto duly executed by
the Holder or its agent or attorney and funds sufficient to pay any
transfer taxes payable upon the making of such transfer. Upon such
surrender and, if required, such payment, the Company shall execute
and deliver a new Warrant or Warrants in the name of the assignee
or assignees, as applicable, and in the denomination or
denominations reasonably requested in such instrument of
assignment, and shall issue to the assignor a new Warrant
evidencing the portion of this Warrant not so assigned, and this
Warrant shall promptly be cancelled. Notwithstanding anything
herein to the contrary, the Holder shall not be required to
physically surrender this Warrant to the Company unless the Holder
has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three (3) Trading Days
of the date the Holder delivers an assignment form to the Company
assigning this Warrant full. The Warrant, if properly
assigned in accordance herewith, may be exercised by a new holder
for the purchase of Warrant Shares without having a new Warrant
issued.
b)
New Warrants
. This Warrant may
be divided or combined with other Warrants upon presentation hereof
at the aforesaid office of the Company, together with a written
notice specifying the names and denominations in which new Warrants
are to be issued, signed by the Holder or its agent or attorney.
Subject to compliance with Section 4(a), as to any transfer which
may be involved in such division or combination, the Company shall
execute and deliver a new Warrant or Warrants in exchange for the
Warrant or Warrants to be divided or combined in accordance with
such notice. All Warrants issued on transfers or exchanges shall be
dated the Initial Exercise Date and shall be substantially
identical with this Warrant except as to the number of Warrant
Shares issuable pursuant thereto.
c)
Warrant Register
. The Company
shall register this Warrant, upon records to be maintained by the
Company for that purpose (the “
Warrant Register
”), in
the name of the record Holder hereof from time to time. The Company
may deem and treat the registered Holder of this Warrant as the
absolute owner hereof for the purpose of any exercise hereof or any
distribution to the Holder, and for all other purposes, absent
actual notice to the contrary.
d)
Transfer
Restrictions
.
If
, at the
time of the surrender of this Warrant in
connection with any transfer of this Warrant, the transfer of this
Warrant shall not be either (i) registered pursuant to an
effective
registration
statement under the Securities Act
and
under applicable state securities or
blue sky laws or (ii) eligible for resale without volume or
manner-of-sale restrictions or current public information
requirements pursuant to Rule 144, the Company may require, as a
condition of allowing such transfer, that the Holder or transferee
of this Warrant, as the case may be, comply with the provisions of
the Purchase Agreement and applicable securities
laws.
e)
Representation by the Holder
.
The Holder, by the acceptance hereof, represents and warrants that
it is acquiring this Warrant and, upon any exercise hereof, will
acquire the Warrant Shares issuable upon such exercise, for its own
account and not with a view to or for distributing or reselling
such Warrant Shares or any part thereof in violation of the
Securities Act or any applicable state securities law, except
pursuant to sales registered or exempted under the Securities
Act.
Section
5
.
Miscellaneous
.
a)
No Rights as Stockholder Until
Exercise
. This Warrant does not entitle the Holder to any
voting rights, dividends or other rights as a stockholder of the
Company prior to the exercise hereof as set forth in Section
2(d)(i), except as expressly set forth in Section 3.
b)
Loss, Theft, Destruction or Mutilation
of Warrant
. The Company covenants that upon receipt by the
Company of evidence reasonably satisfactory to it of the loss,
theft, destruction or mutilation of this Warrant or any stock
certificate relating to the Warrant Shares, and in case of loss,
theft or destruction, of indemnity or security reasonably
satisfactory to it (which, in the case of the Warrant, shall not
include the posting of any bond), and upon surrender and
cancellation of such Warrant or stock certificate, if mutilated,
the Company will make and deliver a new Warrant or stock
certificate of like tenor and dated as of such cancellation, in
lieu of such Warrant or stock certificate.
c)
Saturdays, Sundays, Holidays,
etc
. If the last or appointed day for the taking of any
action or the expiration of any right required or granted herein
shall not be a Business Day, then, such action may be taken or such
right may be exercised on the next succeeding Business
Day.
d)
Automatic Exercise upon
Expiration.
In the event that, upon the Termination Date,
the Per Share Market Value of one share of Common Stock (or other
security issuable upon the exercise hereof) as determined in
accordance with this Warrant above is greater than the Exercise
Price in effect on such date, then this Warrant shall automatically
be deemed on and as of such date to be exercised pursuant to a
Cashless Exercise as to all shares (or such other securities) for
which this Warrant shall not previously have been exercised or
converted, and the Company shall promptly deliver the shares (or
such other securities) issued upon such exercise to the Holder;
provided
,
however
, to the
extent that the foregoing automatic exercise would result in the
Holder exceeding the Beneficial Ownership Limitation, then the
Company shall issue to the Holder such number of Preferred Shares
in an equivalent manner so that the number of Preferred Conversion
Shares underlying such Preferred Shares would equal the number of
Warrant Shares issuable upon such automatic exercise, as would not
result in the Holder exceeding the Beneficial Ownership
Limitation.
e)
Authorized Shares
. The Company
covenants that, during the period the Warrant is outstanding, it
will reserve from its authorized and unissued Common Stock a
sufficient number of shares to provide for the issuance of the
Warrant Shares upon the exercise of any purchase rights under this
Warrant. The Company further covenants that its issuance of this
Warrant shall constitute full authority to its officers who are
charged with the duty of issuing the necessary Warrant Shares upon
the exercise of the purchase rights under this Warrant. The Company
will take all such reasonable action as may be necessary to assure
that such Warrant Shares may be issued as provided herein without
violation of any applicable law or regulation, or of any
requirements of the Trading Market upon which the Common Stock may
be listed. The Company covenants that all Warrant Shares which may
be issued upon the exercise of the purchase rights represented by
this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance
herewith, be duly authorized, validly issued, fully paid and
nonassessable and free from all taxes, liens and charges created by
the Company in respect of the issue thereof (other than taxes in
respect of any transfer occurring contemporaneously with such
issue).
Except
and to the extent as waived or consented to by the Holder, the
Company shall not by any action, including, without limitation,
amending its certificate of incorporation or through any
reorganization, transfer of assets, consolidation, merger,
dissolution, issue or sale of securities or any other voluntary
action, avoid or seek to avoid the observance or performance of any
of the terms of this Warrant, but will at all times in good faith
assist in the carrying out of all such terms and in the taking of
all such actions as may be reasonably necessary or appropriate to
protect the rights of Holder as set forth in this Warrant against
impairment. Without limiting the generality of the foregoing, the
Company will (i) not increase the par value of any Warrant Shares
above the amount payable therefor upon such exercise immediately
prior to such increase in par value, (ii) take all such action as
may be reasonably necessary or appropriate in order that the
Company may validly and legally issue fully paid and nonassessable
Warrant Shares upon the exercise of this Warrant and (iii) use
commercially reasonable efforts to obtain all such authorizations,
exemptions or consents from any public regulatory body having
jurisdiction thereof, as may be, reasonably necessary to enable the
Company to perform its obligations under this Warrant.
Before
taking any action which would result in an adjustment in the number
of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or
exemptions thereof, or consents thereto, as may be reasonably
necessary from any public regulatory body or bodies having
jurisdiction thereof.
f)
Governing Law; Jurisdiction
.
This Warrant shall be governed by and construed in accordance with
the internal laws of the State of New York, without giving effect
to any of the conflicts of law principles which would result in the
application of the substantive law of another jurisdiction. Each of
the Company and the Holder (i) hereby irrevocably submits to the
jurisdiction of the United States District Court sitting in the
Southern District of New York and the courts of the State of New
York located in New York county for the purposes of any suit,
action or proceeding arising out of or relating to this Warrant or
any of the other Transaction Documents or the transactions
contemplated hereby or thereby and (ii) hereby waives, and agrees
not to assert in any such suit, action or proceeding, any claim
that it is not personally subject to the jurisdiction of such
court, that the suit, action or proceeding is brought in an
inconvenient forum or that the venue of the suit, action or
proceeding is improper.
g)
Restrictions
. The Holder
acknowledges that the Warrant Shares acquired upon the exercise of
this Warrant will have restrictions upon resale imposed by state
and federal securities laws.
h)
Nonwaiver and Expenses
. No
course of dealing or any delay or failure to exercise any right
hereunder on the part of Holder shall operate as a waiver of such
right or otherwise prejudice the Holder’s rights, powers or
remedies, notwithstanding the fact that all rights hereunder
terminate on the Termination Date. If the Company willfully and
knowingly fails to comply with any provision of this Warrant, which
results in any material damages to the Holder, the Company shall
pay to the Holder such amounts as shall be sufficient to cover any
costs and expenses including, but not limited to, reasonable
attorneys’ fees, including those of appellate proceedings,
incurred by the Holder in collecting any amounts due pursuant
hereto or in otherwise enforcing any of its rights, powers or
remedies hereunder.
i)
Notices
. Any and all notices or
other communications or deliveries required or permitted to be
provided hereunder shall be in writing and shall be deemed given
and effective on the earliest of: (a) the date of transmission, if
such notice or communication is delivered via facsimile or email at
the facsimile number or email address of the addressee at or prior
to 5:30 p.m. (New York City time) on a Trading Day, (b) the next
Trading Day after the date of transmission, if such notice or
communication is delivered via facsimile or email at the facsimile
number or email address of the addressee on a day that is not a
Trading Day or later than 5:30 p.m. (New York City time) on any
Trading Day, (c) the second (2
nd
) Trading Day
following the date of mailing, if sent by U.S. nationally
recognized overnight courier service or (d) upon actual receipt by
the party to whom such notice is required to be given. The address
for such notices and communications shall be as set forth in the
Company’s records.
j)
Limitation of Liability
. No
provision hereof, in the absence of any affirmative action by the
Holder to exercise this Warrant to purchase Warrant Shares, and no
enumeration herein of the rights or privileges of the Holder, shall
give rise to any liability of the Holder for the purchase price of
any Common Stock or as a stockholder of the Company, whether such
liability is asserted by the Company or by creditors of the
Company.
k)
Remedies
. The Holder, in
addition to being entitled to exercise all rights granted by law,
including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees
that monetary damages would not be adequate compensation for any
loss incurred by reason of a breach by it of the provisions of this
Warrant and hereby agrees to waive and not to assert the defense in
any action for specific performance that a remedy at law would be
adequate.
l)
Successors and Assigns
. Subject
to applicable securities laws, this Warrant and the rights and
obligations evidenced hereby shall inure to the benefit of and be
binding upon the successors and permitted assigns of the Company
and the successors and permitted assigns of Holder. The provisions
of this Warrant are intended to be for the benefit of any Holder
from time to time of this Warrant and shall be enforceable by the
Holder or holder of Warrant Shares.
m)
Amendment
. This Warrant may be
modified or amended or the provisions hereof waived with the prior
written consent of the Company and the holders of a majority of the
Warrant Shares underlying the then outstanding Warrants issued
pursuant to the
Purchase
Agreement
.
n)
Severability
. Wherever
possible, each provision of this Warrant shall be interpreted in
such manner as to be effective and valid under applicable law, but
if any provision of this Warrant shall be prohibited by or invalid
under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the
remainder of such provisions or the remaining provisions of this
Warrant.
o)
Headings
. The headings used in
this Warrant are for the convenience of reference only and shall
not, for any purpose, be deemed a part of this
Warrant.
********************
IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed
by its officer thereunto duly authorized as of the date first above
indicated.
METASTAT, INC.
|
By:__________________________________________
Name:
Title:
|
NOTICE OF EXERCISE
(1)
The undersigned
hereby elects to purchase ________ Warrant Shares of the Company
pursuant to the terms of the attached Warrant (only if exercised in
full), and tenders herewith payment of the exercise price in full,
together with all applicable transfer taxes, if any.
(2)
Please issue a
certificate or certificates representing said Warrant Shares in the
name of the undersigned or in such other name as is specified
below:
_______________________________
The
Warrant Shares shall be delivered to the following DWAC Account
Number or by physical delivery of a certificate to:
_______________________________
_______________________________
_______________________________
(3)
Accredited
Investor
. The undersigned is an “accredited
investor” as defined in Regulation D promulgated under the
Securities Act of 1933, as amended.
(4)
The undersigned
intends that payment of the Exercise Price shall be made as (check
one):
Cash
Exercise_______
Cashless
Exercise_______
If the
Holder has elected a Cash Exercise, the Holder shall pay the sum of
$________ by certified or official bank check (or via wire
transfer) to the Company in accordance with the terms of the
Warrant.
If the
Holder has elected a Cashless Exercise, a certificate shall be
issued to the Holder for the number of shares equal to the whole
number portion of the product of the calculation set forth below,
which is ___________. The Company shall pay a cash adjustment in
respect of the fractional portion of the product of the calculation
set forth below in an amount equal to the product of the fractional
portion of such product and the Per Share Market Value on the date
of exercise, which product is ____________.
X = Y x
(B-A)
B
Where:
The
number of shares of Common Stock to be issued to the Holder is
(“X”).
The
number of shares of Common Stock purchasable upon exercise of all
of the Warrant or, if only a portion of the Warrant is being
exercised, the portion of the Warrant being exercised is
(“Y”).
The
Exercise Price is (“A”).
The Per
Share Market Value of one share of Common Stock is
(“B”).
[SIGNATURE
OF HOLDER]
Name of
Investing Entity:
_________________________________________________________________
Signature of Authorized Signatory of Investing
Entity
:
___________________________________________
Name of
Authorized Signatory:
_____________________________________________________________
Title
of Authorized Signatory:
______________________________________________________________
Date:
__________________________________________________________________________________
ASSIGNMENT FORM
(To
assign the foregoing warrant, execute
this
form and supply required information.
Do not
use this form to exercise the warrant.)
FOR
VALUE RECEIVED, [____ all of or [_______ shares of the foregoing
Warrant and all rights evidenced thereby are hereby assigned
to
_______________________________________________
whose address is
_______________________________________________________________.
_______________________________________________________________
Dated:
______________, _______
Holder’s
Signature:
_____________________________
Holder’s
Address:
_____________________________
_____________________________
Exhibit 10.1
NOTE PURCHASE AGREEMENT
This Note Purchase Agreement (this
“
Agreement
”)
is made as of March 30, 2018 by and between MetaStat, Inc. (the
“
Company
”),
a Nevada corporation, with offices at 27 Drydock Ave.,
2
nd
Floor, Boston MA 02210 and the
purchasers listed on
Exhibit A
attached hereto (the
“
Purchasers
”).
WHEREAS,
the Company
desires
to sell to the Purchasers, and the Purchasers
desire to purchase from the Company
through a private
placement (the “
Offering
”)
, (i) senior non-convertible promissory bridge
notes in the aggregate principal amount of up to $2,334,027 (the
“
Senior
Notes
”), (ii) junior
non-convertible promissory bridge notes in the aggregate principal
amount of $1,294,900 (the “
Junior
Notes
” and, together with
the Senior Notes, the “
Notes
”),
and (iii) warrants to purchase shares of Common Stock (the
“
Note
Warrants
”);
and
WHEREAS
, the Company and
each of the Purchasers are executing and delivering this Agreement
in accordance with and in reliance
upon
the exemption from securities
registration afforded by Section 4(a)(2) of the Securities Act and
Rule 506(b) of Regulation D (“
Regulation D
”) as
promulgated by the United States Securities and Exchange Commission
(the “
Commission
”) under the
Securities Act of 1933, as amended (the “
Securities Act
”);
and
WHEREAS
, the Offering is being conducted
through Alere Financial Partners, LLC, a division of Cova Capital
Partners, LLC, a non-exclusive registered placement agent (the
“
Agent
”).
NOW, THEREFORE,
in consideration of the premises and
mutual covenants and obligations hereinafter set forth and other
good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, the Company and the Purchasers,
intending to be legally bound, hereby agree as
follows:
ARTICLE I
Definitions
Section
1.1
Certain Definitions
. When used
herein, the following terms shall have the respective meanings
indicated:
“
Board of Directors
” means
the Company’s board of directors.
“
Business Day
” means any
day other than a Saturday, a Sunday or a day on which the OTCQB (or
other principal exchange) is closed or on which banks in the City
of New York are required or authorized by law to be
closed.
“
Common Stock
” means
shares of the Company’s common stock, par value $0.0001 per
share.
“
Exchange Act
” means the
Securities Exchange Act of 1934, as amended (or any successor act),
and the rules and regulations thereunder (or respective successors
thereto).
“
Indebtedness
” shall mean
(a) any liabilities for borrowed money or amounts owed (other than
trade accounts payable incurred in the ordinary course of
business), (b) all guaranties, endorsements and other contingent
obligations in respect of Indebtedness of others, whether or not
the same should be reflected in the Company’s consolidated
balance sheet (or the notes thereto), except guaranties by
endorsement of negotiable instruments for deposit or collection or
similar transactions in the ordinary course of business; and (c)
the present value of any lease payments due under leases required
to be capitalized in accordance with U.S. GAAP, except in each of
the foregoing cases (a) through (c), for Permitted
Indebtedness.
“
Intellectual Property
Rights
” means all U.S. and foreign patents,
trademarks, domain names (whether or not registered) and any
patentable improvements or copyrightable derivative works thereof,
websites and intellectual property rights relating thereto, service
marks, trade names, copyrights, licenses and authorizations, if
any, and all rights with respect to the foregoing, if any, which
are necessary for the conduct of their respective business as now
conducted without any conflict with the rights of others, except
where the failure to so own or possess would not have a Material
Adverse Effect.
“
Lien
” means, with respect
to any Property, any mortgage, pledge, hypothecation, assignment,
deposit arrangement, security interest, tax lien, financing
statement, pledge, charge, or other lien, easement, encumbrance,
preference, priority or other security agreement or preferential
arrangement of any kind or nature whatsoever on or with respect to
such Property (including, without limitation, any conditional sale
or other title retention agreement having substantially the same
economic effect as any of the foregoing), except in each of the
foregoing cases for Permitted Liens.
“
Material Adverse Effect
”
means any material adverse effect on the business, operations,
properties, or financial condition of the Company and its
Subsidiaries, taken as a whole, and/or any condition, circumstance,
or situation that would prohibit or otherwise materially interfere
with the ability of the Company to perform any of its obligations
under this Agreement in any material respect.
“
Permitted Indebtedness
”
means Indebtedness incurred (a) in the ordinary course of business,
which shall include trade payables and accruals in accordance with
the Company’s past practice, and (b) from any participant in
a strategic transaction with the Company that has been approved by
a majority of the disinterested directors of the Company, provided
that (A) any such Indebtedness shall only be incurred from a person
that is, itself or through its Subsidiaries, an operating company
in a business synergistic with the business of the Company and in
which the Company receives benefits in addition to the investment
of funds, and (B) the primary purpose of such Indebtedness is not
to raise capital.
“
Permitted Liens
” means:
(1) liens in connection with the purchase of equipment secured by
such equipment; (2) liens to secure the performance of statutory
obligations, surety or appeal bonds, performance bonds or other
obligations of a like nature, in each case, other than for the
payment of debt incurred in the ordinary course of business; (3)
liens for taxes, assessments or governmental charges or claims that
are not yet delinquent or that are being contested in good faith by
appropriate proceedings promptly instituted and diligently
concluded; provided that any reserve or other appropriate provision
as is required in conformity with GAAP has been made therefor; (4)
pledges or deposits by a person under worker’s compensation
laws, unemployment insurance laws or similar legislation; (5) liens
imposed by law, such as carriers’, warehousemen’s,
landlord’s and mechanics’ liens, in each case, incurred
in the ordinary course of business; (6) judgment liens not giving
rise to an Event of Default (as defined in the Notes) so long as
such lien is adequately bonded and any appropriate legal
proceedings which may have been duly initiated for the review of
such judgment shall not have been finally terminated or the period
within which such proceedings may be initiated shall not have
expired; (7) liens arising solely by virtue of any statutory or
common law provision relating to banker’s liens, rights of
set-off or similar rights and remedies as to deposit accounts or
other funds maintained with a creditor depository institution; and
(8) liens under licensing agreements entered into by the Company
for use of intellectual property entered into in the ordinary
course of business.
“
Promissory Note
” means
the 10% convertible promissory note issued by the Company pursuant
to that certain Exchange Agreement dated January 17, 2017, in the
aggregate principal amount of $1,000,000 plus all accrued and
unpaid interest thereon, which is convertible into shares of Common
Stock at $2.00 per share and has a maturity date of September 30,
2017.
“
Promissory Note Exchange
”
means the exchange of the Promissory Note at the Promissory Note
Exchange Amount into Senior Notes and Note Warrants pursuant
hereto
.
“
Promissory Note Exchange
Amount
” means $834,027.00.
“
Property
” means property
and/or assets of all kinds, whether real, personal or mixed,
tangible or intangible (including, without limitation, all rights
relating thereto.
“
Rule 144
” means Rule 144
of the Commission, as amended, promulgated pursuant to the
Securities Act or any successor provision.
“
Securities
” means the
Notes, the Note Warrants and the Warrant Shares that may be issued
pursuant to Article 2 herein.
“
Series B Preferred
” means
the shares of the Company’s Series B Convertible Preferred
Stock with a stated value of $5,500 per share, originally issued by
the Company pursuant that certain Securities Purchase Agreement
dated December 31, 2014, as amended March 27, 2015, plus all
accrued and unpaid dividends thereon, which is convertible into
shares of Common Stock at $0.83 per share.
“
Series B Exchange
” means
the exchange of the Series B Preferred at the Series B Exchange
Amount into Junior Notes and Note Warrants pursuant
hereto
.
“
Series B Exchange Amount
”
means $1,294,900.00.
“
Short Sales
” means all
“short sales” as defined in Rule 200 of Regulation SHO
under the Securities Exchange Act of 1934 (but shall not be deemed
to include the location and/or reservation of borrowable shares of
Common Stock).
“
Subsidiary
” means any
corporation or other entity of which at least a majority of the
securities or other ownership interests having ordinary voting
power (absolutely or contingently) for the election of directors or
other persons performing similar functions are at the time owned
directly or indirectly by the Company and/or any of its other
Subsidiaries.
“
Trading Day
” means a day
on which the OTCQB is open for trading.
“
Transaction Documents
”
means this Agreement, the Notes, the Note Warrants, the Exchange
Agreement, the Confidential Private Purchaser Questionnaire and all
other, agreements, documents, and other instruments executed and
delivered by or on behalf of the Company in connection with the
Offering.
“
U.S. GAAP
” means United
States generally accepted accounting principles, applied on a
consistent basis, as set forth in (i) opinions of the Accounting
Principles Board of the American Institute of Certified Public
Accountants, (ii) statements of the Financial Accounting Standards
Board and (iii) interpretations of the Commission and the Staff of
the Commission. Accounting principles are applied on a
“consistent basis” when the accounting principles
applied in a current period are comparable in all material respects
to those accounting principles applied in a preceding period,
except to the extent that new accounting standards have been
adopted by such organizations applicable as of the current
period.
ARTICLE II
Purchase and Sale
of the Securities
Section
2.1
Purchase and Sale of the
Securities
. Upon the following terms and conditions, the
Company is offering to each Purchaser and each Purchaser is
purchasing from the Company the number of Securities set forth
opposite such Purchaser’s name on
Exhibit A
attached
hereto.
Section
2.2
Notes
. Subject to the terms and
conditions hereof, the Company agrees to issue and sell to the
Purchasers and the Purchasers agree to purchase from the Company,
at the Closing (as defined below), the Senior Notes and Junior
Notes, as set forth opposite such Purchaser’s name on
Exhibit A
attached
hereto. The Junior Notes shall be issued solely pursuant to the
Series B Exchange. The terms of the Senior Notes shall be
substantially as set forth in the form of Senior Note attached
hereto as
Exhibit
B-1
and the terms of the Junior Notes shall be substantially
as set forth in the form of Junior Note attached hereto as
Exhibit B-2
. This
purchase commitment is made in accordance with and subject to the
terms and conditions described in this Agreement.
Section
2.3
Note Warrants
. Each of the
Purchasers shall be issued Note Warrants on a pro rata basis to
purchase an aggregate of 10,000 shares of Common Stock (each a
“
Warrant
Share
” and collectively, the “
Warrant Shares
”) for each
$100,000
principal amount of Notes
issued pursuant hereto
. The Note Warrants, in substantially
the form attached hereto as
Exhibit C,
shall expire five
(5) years following the applicable Closing Date and have an initial
exercise price per Warrant Share of $2.00.
Section
2.4
Warrant Shares
. The Company has
authorized and has reserved and covenants and agrees to continue to
reserve, free of all preemptive rights and other similar
contractual rights of stockholders and/or others, a number of
shares of Common Stock equal to one hundred percent (100%) of the
number of Warrant Shares as shall from time to time be sufficient
to effect exercise of all of the Note Warrants then
outstanding.
Section
2.5
Purchase Price and Closing.
Subject to the terms and conditions hereof, the Company agrees to
issue and sell to the Purchasers and, in consideration of and in
express reliance upon the representations, warranties, covenants,
terms and conditions of this Agreement, the Purchasers, severally
but not jointly, agree to purchase the Securities set forth
opposite their respective names on
Exhibit A
attached hereto for
an aggregate purchase price of up to $3,628,927 (the
“
Purchase
Price
”),
provided
,
however
, that a portion of the
Purchase Price shall be paid by certain Purchasers in connection
with the Promissory Note Exchange pursuant to Section 2.6 below and
by certain Purchasers in connection with the Series B Exchange
pursuant to Section 2.7 below. The initial closing (the
“
Initial
Closing
”) of the purchase and sale of the Securities
to be acquired by the Purchasers from the Company under this
Agreement shall take place at such time as Purchasers have executed
this Agreement, and all of the conditions set forth in Article V
hereof and applicable to the Initial Closing shall have been
fulfilled or waived in accordance herewith (the “
Initial Closing Date
”).
After the Initial Closing, the Company may conduct any number of
additional closings (each, an “
Additional Closing
” and,
together with the Initial Closing, a “
Closing
”) so long as the
final Additional Closing occurs on or before April 6, 2018, unless
mutually extended by the Company and the Agent. Subject to all
conditions to Closing have been satisfied or waived, each Closing
shall take place at such time and place as the parties shall agree
(a “
Closing
Date
”).
Section
2.6
Exchange of Promissory Note.
The parties hereto acknowledge and agree that, at and as a
condition to Purchasers purchasing the Securities at the Initial
Closing, the holder of the Promissory Note shall enter into an
exchange agreement (the “
Exchange Agreement
”) in
substantially the form attached hereto as Exhibit D, and
accordingly be deemed a Purchaser under this Agreement and parties
to the other Transaction Documents, and in connection with the
Promissory Note Exchange will receive (i) Senior Notes with a
principal amount equal to the Promissory Note Exchange Amount and
(ii) Note Warrants based on the formula set forth in Section 2.3
hereof. The parties agree that the Promissory Note Exchange Amount
shall be deemed to constitute a portion of the Purchase Price for
purposes of this Agreement, including, without limitation, Section
2.5 hereof.
Section
2.7
Exchange of Series B Preferred.
The parties hereto acknowledge and agree that, at and as a
condition to Purchasers purchasing the Securities at the Initial
Closing, the holder of the Series B Preferred shall enter into the
Exchange Agreement, and accordingly be deemed a Purchaser under
this Agreement and parties to the other Transaction Documents, and
in connection with the Series B Exchange will receive (i) Junior
Notes with a principal amount equal to the Series B Exchange Amount
and (ii) Note Warrants based on the formula set forth in Section
2.3 hereof. The parties agree that the Series B Exchange Amount
shall be deemed to constitute a portion of the Purchase Price for
purposes of this Agreement, including, without limitation, Section
2.5 hereof.
Section
2.8
Payment, Escrow Agent, and Obligations
of the Escrow Agent
.
(a)
Each
Purchaser’s appropriate cash Purchase Price (i.e., a purchase
price equal to the principal amount of Notes to be purchased by
such Purchaser) as set forth on
Exhibit A
attached hereto,
shall be paid to Signature Bank, as escrow agent for MetaStat, Inc.
(the “
Escrow
Agent
”), by wire transfer of immediately available
funds in U.S. dollars (or in the form of a personal or
cashier’s check) in accordance with the wire and delivery
instructions attached hereto as
Exhibit E
. The Purchase Price
shall accompany the delivery of the executed Transaction Documents
by such Purchaser.
(b)
The Purchaser
acknowledges and agrees that this Agreement and any other documents
delivered in connection herewith will be held by the Agent on
behalf of the Company, and the Purchase Price will be deposited in
an escrow account (the “
Escrow Account
”), held by
the Escrow Agent. In the event that this Agreement is not accepted
in whole or in part by the Company for whatever reason, this
Agreement and any other documents delivered in connection herewith
will be returned to the Purchaser by the Agent at the address of
the Purchaser as set forth on the Purchaser’s signature page
hereto, and any Purchase Price deposited in the Escrow Account
shall be returned to the Purchaser by the Escrow Agent in
accordance with the payment information provided by the Agent to
the Escrow Agent.
(c)
The Purchaser
agrees that the Escrow Agent shall have no accountability or
obligations to the Purchaser whatsoever and acknowledges that the
Escrow Agent is accountable only to the Company and the Agent. The
Purchaser agrees that when the Purchase Price is deposited in the
Escrow Account, the Escrow Agent’s only duty shall be to
deliver the Purchase Price to the Company or its designees, all
solely according to payment instructions submitted jointly by the
Company and the Agent (the “
Payment Instructions
”),
and the Escrow Agent shall require no further instructions from the
Purchaser in delivering the same to the Company or its designees.
The Escrow Agent shall upon notice of a Closing Date jointly from
the Company and the Agent, release to the Company or its designees
the proceeds of the Offering in accordance with the Payment
Instructions. In the event the Company rejects the purchase
pursuant to this Agreement in whole or in part, the Escrow Agent
shall return such Purchaser’s Purchase Price directly to the
Purchaser without interest or deduction there from. The proceeds of
the Escrow Account shall be distributed in accordance with Section
2.5.
ARTICLE III
Representations and Warranties
Section
3.1
Representations and Warranties of the
Company
. The Company hereby represents and warrants to the
Purchasers, as of the date hereof (except as set forth on the
Company Disclosure Schedule attached hereto with each numbered
Schedule corresponding to the section number herein) and as of each
Closing Date (except for the representations and warranties that
speak as of a specific date, which shall be made as of such date),
as follows:
(a)
Organization, Good Standing and
Power
. The Company is a corporation duly incorporated,
validly existing and in good standing under the laws of the State
of Nevada and has the requisite corporate power to own, lease and
operate its properties and assets and to conduct its business as it
is now being conducted. The Company is duly qualified to do
business and is in good standing in every jurisdiction in which the
nature of the business conducted or property owned by it makes such
qualification necessary except for any jurisdiction(s) (alone or in
the aggregate) in which the failure to be so qualified will not
have a Material Adverse Effect on the Company’s consolidated
financial condition.
(b)
Corporate Power; Authority and
Enforcement
. The Company has the requisite corporate power
and authority to enter into and perform this Agreement and the
other Transaction Documents, and to issue and sell the Securities
in accordance with the terms hereof and thereof. The execution,
delivery and performance of this Agreement and the other
Transaction Documents by the Company and the consummation by it of
the transactions contemplated hereby and thereby have been duly and
validly authorized by all necessary corporate action, and no
further consent or authorization of the Company or its Board of
Directors or stockholders is required. Each of the Transaction
Documents constitutes, or shall constitute when executed and
delivered, a valid and binding obligation of the Company
enforceable against the Company in accordance with its terms,
except as such enforceability may be limited by applicable
bankruptcy, insolvency, reorganization, moratorium, liquidation,
conservatorship, receivership or similar laws relating to, or
affecting generally the enforcement of, creditor’s rights and
remedies or by other equitable principles of general
application.
(c)
Capitalization
. The authorized
capital stock of the Company and the shares thereof currently
issued and outstanding as of the date hereof is set forth on
Schedule 3.1(c)
hereto. All of the outstanding shares of capital stock of the
Company are duly authorized, validly issued, fully paid and
nonassessable, have been issued in compliance with all applicable
federal and state securities laws, and none of such outstanding
shares was issued in violation of any preemptive rights or similar
rights to subscribe for or purchase securities. Except as
contemplated by the Transaction Documents or as set forth on
Schedule 3.1(c)
hereto:
(i)
no shares of Common
Stock are entitled to preemptive, conversion or other rights and
there are no outstanding options, warrants, scrip, rights to
subscribe to, call or commitments of any character whatsoever
relating to, or securities or rights convertible into, any shares
of capital stock of the Company;
(ii)
there
are no contracts, commitments, understandings, or arrangements by
which the Company is or may become bound to issue additional shares
of capital stock of the Company or options, securities or rights
convertible into shares of capital stock of the
Company;
(iii)
the
Company is not a party to any agreement granting registration or
anti-dilution rights to any person with respect to any of its
equity or debt securities; and
(iv)
the
Company is not a party to, and it has no knowledge of, any
agreement restricting the voting or transfer of any shares of the
capital stock of the Company.
The
offer and sale of all capital stock, convertible securities,
rights, warrants, or options of the Company issued prior to the
Closing complied in all material respects with all applicable
federal and state securities laws. The Company has furnished or
made available to the Purchasers true and correct copies of the
Company’s Articles of Incorporation, as amended and in effect
on the date hereof (the “
Articles
”), and the
Company’s Bylaws, as amended and in effect on the date hereof
(the “
Bylaws
”). Except as
restricted under applicable federal, state, local or foreign laws
and regulations, the Transaction Documents, or as set forth on
Schedule 3.1(c)
, no
written or oral contract, instrument, agreement, commitment,
obligation, plan or arrangement of the Company shall limit the
payment of dividends on the Common Stock.
(d)
Issuance of Securities, Etc
.
The Securities to be issued at the Closing have been duly
authorized by all necessary corporate action and the Notes and Note
Warrants when paid for or issued in accordance with the terms
hereof, will be validly issued and outstanding, fully paid and
nonassessable and, immediately after the Closing, the Purchasers
will be the owners of all of such securities and have good and
valid title to all of such securities, free and clear of all
encumbrances, except as may be imposed under federal and state
securities laws. When any Warrant Shares are issued in accordance
with the exercise of the Warrants, such Warrant Shares will be duly
authorized by all necessary corporate action and validly issued and
outstanding, fully paid and nonassessable, and the holders will be
entitled to all rights accorded to a holder of Common Stock and
will be the record and beneficial owners of all of such securities
and have good and valid title to all of such securities, free and
clear of all encumbrances.
(e)
Subsidiaries
.
Schedule 3.1(e)
hereto sets
forth each Subsidiary of the Company, showing the jurisdiction of
its incorporation or organization and showing the percentage of
ownership of each Subsidiary. Each Subsidiary has been duly
incorporated or otherwise organized and is validly existing and in
good standing in each of their respective jurisdictions of
incorporation or organization. Each Subsidiary is duly qualified to
do business and is in good standing in every jurisdiction in which
the nature of the business conducted or property owned by it makes
such qualification necessary except for any jurisdiction(s) (alone
or in the aggregate) in which the failure to be so qualified will
not have a Material Adverse Effect. There are no outstanding
preemptive, conversion or other rights, options, warrants or
agreements granted or issued by or binding upon any Subsidiary for
the purchase or acquisition of any shares of capital stock of any
Subsidiary or any other securities convertible into, exchangeable
for or evidencing the rights to subscribe for any shares of such
capital stock. Neither the Company nor any Subsidiary is subject to
any obligation (contingent or otherwise) to repurchase or otherwise
acquire or retire any shares of the capital stock of any Subsidiary
or any convertible securities, rights, warrants or options of the
type described in the preceding sentence. Except as filed as
exhibits to the Commission Documents (as defined below), neither
the Company nor any Subsidiary is party to, nor has any knowledge
of, any agreement restricting the voting or transfer of any shares
of the capital stock of any Subsidiary.
(f)
Commission Documents, Financial
Statements
. For the two-year period preceding the date
hereof, the Company has filed all reports, schedules, forms,
statements and other documents required to be filed by it with the
Commission pursuant to the reporting requirements of the Exchange
Act, including material filed pursuant to Section 13(a) or 15(d) of
the Exchange Act (all of the foregoing including filings
incorporated by reference therein being referred to herein as the
“
Commission
Documents
”). The Company has not provided to the
Purchasers any material non-public information or other information
which, according to applicable law, rule or regulation, was
required to have been disclosed publicly by the Company but which
has not been so disclosed, other than (i) with respect to the
transactions contemplated by this Agreement, or (ii) pursuant to a
non-disclosure or confidentiality agreement signed by the
Purchasers. At the time of the respective filings, the Commission
Documents filed during the two-year period preceding the date
hereof complied in all material respects with the requirements of
the Exchange Act and the rules and regulations of the Commission
promulgated thereunder and other federal, state and local laws,
rules and regulations applicable to such documents. None of the
Commission Documents, when filed, contained any untrue statement of
a material fact or omitted to state a material fact required to be
stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they were
made, not misleading. The financial statements of the Company
included in the Commission Documents (the “
Financial Statements
”)
complied as of their respective filing dates as to form in all
material respects with applicable accounting requirements and the
published rules and regulations of the Commission or other
applicable rules and regulations with respect thereto. The
Financial Statements have been prepared in accordance U.S. GAAP
during the periods involved (except (i) as may be otherwise
indicated in the Financial Statements or the notes thereto or (ii)
in the case of unaudited interim statements, to the extent they may
not include footnotes or may be condensed or summary statements),
and fairly present in all material respects the consolidated
financial position of the Company as of the dates thereof and the
results of operations and cash flows for the periods then ended
(subject, in the case of unaudited statements, to normal year-end
audit adjustments).
(g)
No Material Adverse Effect
.
Since February 28, 2017, neither the Company nor any Subsidiary has
experienced or suffered any Material Adverse Effect.
(h)
No Undisclosed Liabilities
.
Other than as disclosed on
Schedule 3.1(h
) or set forth in
the Commission Documents, neither the Company nor the Subsidiary
has any liabilities, obligations, claims or losses (whether
liquidated or unliquidated, secured or unsecured, absolute,
accrued, contingent or otherwise) other than those incurred in the
ordinary course of the Company’s business since February 28,
2017 and those which, individually or in the aggregate, do not have
a Material Adverse Effect.
(i)
No Undisclosed Events or
Circumstances
. No event or circumstance has occurred or
exists with respect to the Company or any Subsidiary or their
respective businesses, properties, operations or financial
condition, which, under applicable law, rule or regulation,
requires public disclosure or announcement by the Company but which
has not been so publicly announced or disclosed.
(j)
Indebtedness
. The Financial
Statements set forth all outstanding secured and unsecured
Indebtedness of the Company on a consolidated basis, or for which
the Company or any Subsidiary have commitments as of the date of
Financial Statements or any subsequent period that would require
disclosure. Neither the Company nor any Subsidiary is in default
with respect to any Indebtedness which, individually or in the
aggregate, would have a Material Adverse Effect.
(k)
Title to Assets
. Each of the
Company and its Subsidiaries has good and marketable title to (i)
all properties and assets purportedly owned or used by them as
reflected in the Financial Statements, (ii) all properties and
assets necessary for the conduct of their business as currently
conducted, and (iii) all of the real and personal property
reflected in the Financial Statements free and clear of any Lien.
All leases are valid and subsisting and in full force and
effect.
(l)
Actions Pending
. There is no
action, suit, claim, investigation, arbitration, alternate dispute
resolution proceeding or any other proceeding pending or, to the
knowledge of the Company, threatened against or involving the
Company or any Subsidiary (i) which questions the validity of this
Agreement or any of the other Transaction Documents or the
transactions contemplated hereby or thereby or any action taken or
to be taken pursuant hereto or thereto or (ii) involving any of
their respective properties or assets. To the knowledge of the
Company, there are no outstanding orders, judgments, injunctions,
awards or decrees of any court, arbitrator or governmental or
regulatory body against the Company or any Subsidiary or any of
their respective executive officers or directors in their
capacities as such.
(m)
Compliance with Law
. The
Company and each Subsidiary have all franchises, permits, licenses,
consents and other governmental or regulatory authorizations and
approvals necessary for the conduct of their respective business as
now being conducted by it unless the failure to possess such
franchises, permits, licenses, consents and other governmental or
regulatory authorizations and approvals, individually or in the
aggregate, could not reasonably be expected to have a Material
Adverse Effect.
(n)
No Violation of Law.
The
business of the Company and each Subsidiary is not being conducted
in violation of any federal, state, local or foreign governmental
laws, or rules, regulations and ordinances of any of any
governmental entity, except for possible violations which
singularly or in the aggregate could not reasonably be expected to
have a Material Adverse Effect. The Company is not required under
federal, state, local or foreign law, rule or regulation to obtain
any consent, authorization or order of, or make any filing or
registration with, any court or governmental agency in order for it
to execute, deliver or perform any of its obligations under the
Transaction Documents, or issue and sell the Securities in
accordance with the terms hereof or thereof (other than (x) any
consent, authorization or order that has been obtained as of the
date hereof, (y) any filing or registration that has been made as
of the date hereof or (z) any filings which may be required to be
made by the Company with the Commission or state securities
administrators subsequent to the Closing).
(o)
No Conflicts
. The execution,
delivery and performance of the Transaction Documents by the
Company and the consummation by the Company of the transactions
contemplated herein and therein do not and will not (i) violate any
provision of the Articles or Bylaws, (ii) conflict with, or
constitute a default (or an event which with notice or lapse of
time or both would become a default) under, or give to others any
rights of termination, amendment, acceleration or cancellation of,
any agreement, mortgage, deed of trust, indenture, note, bond,
license, lease agreement, instrument or obligation to which the
Company is a party or by which it or its properties or assets are
bound, (iii) create or impose a Lien or (iv) result in a violation
of any federal, state, local or foreign statute, rule, regulation,
order, judgment or decree (including federal and state securities
laws and regulations) applicable to the Company or any of its
Subsidiaries or by which any Property or asset of the Company or
any of its Subsidiaries are bound or affected,
provided
,
however
, that, excluded from
(ii)-(iv) above are such conflicts, defaults, terminations,
amendments, accelerations, cancellations and violations as would
not, individually or in the aggregate, have a Material Adverse
Effect.
(p)
Taxes
. The Company and each
Subsidiary, to the extent its applicable, has accurately prepared
and filed all federal, state and other tax returns required by law
to be filed by it, has paid or made provisions for the payment of
all taxes shown to be due and all additional assessments, and
adequate provisions have been and are reflected in the consolidated
financial statements of the Company for all current taxes and other
charges to which the Company or any Subsidiary, if any, is subject
and which are not currently due and payable. None of the federal
income tax returns of the Company have been audited by the Internal
Revenue Service. The Company has no knowledge of any additional
assessments, adjustments or contingent tax liability (whether
federal, state or foreign) of any nature whatsoever, whether
pending or threatened against the Company or any Subsidiary for any
period, nor of any basis for any such assessment, adjustment or
contingency.
(q)
Certain Fees
. Except as set
forth on
Schedule
3.1(q)
hereto, no brokers fees, finders’ fees or
financial advisory fees or commissions will be payable by the
Company with respect to the transactions contemplated by this
Agreement and the other Transaction Documents.
(r)
Intellectual Property
. Each of
the Company and its Subsidiaries owns or has the lawful right to
use all Intellectual Property Rights. The Company has not received
a written notice that any of the Intellectual Property Rights used
by the Company violates or infringes upon the rights of any person.
There is no pending or, to the Company’s knowledge,
threatened action, suit, proceeding or claim by any person that the
Company’s business as now conducted infringes or otherwise
violates any patent, trademark, copyright, trade secret or other
proprietary rights of another. To the Company’s knowledge,
there is no existing infringement by another person of any of the
Intellectual Property Rights that would have or would reasonably be
expected to have a Material Adverse Effect. The Company has taken
reasonable security measures to protect the secrecy,
confidentiality and value of all of its Intellectual Property
Rights, except where failure to do so could not, individually or in
the aggregate, reasonably be expected to have a Material Adverse
Effect.
(s)
Books and Records; Internal Accounting
Controls
. The books and records of the Company and each
Subsidiary accurately reflect in all material respects the
information relating to the business of the Company and the
Subsidiaries. Except as disclosed on
Schedule 3.1(s),
the Company
and each Subsidiary maintains a system of “internal control
over financial reporting” (as defined in Rule 13a-15(f)
and 15d-15(f) of the Exchange Act) sufficient to provide reasonable
assurance that (i) transactions are executed in accordance
with management’s general or specific authorizations;
(ii) transactions are recorded as necessary to permit
preparation of financial statements in conformity with U.S. GAAP
and to maintain asset and liability accountability;
(iii) access to assets is permitted only in accordance with
management’s general or specific authorization; and
(iv) the recorded accountability for assets and liabilities is
compared with the existing assets and liabilities at reasonable
intervals and appropriate action is taken with respect to any
differences.
(t)
Material Agreements
. Any and
all written or oral contracts, instruments, agreements,
commitments, obligations, plans or arrangements, the Company and
each Subsidiary is a party to, that a copy of which would be
required to be filed with the Commission as an exhibit to a
registration statement on Form S-1 (collectively, the
“
Material
Agreements
”) if the Company or any Subsidiary were
registering securities under the Securities Act has previously been
publicly filed with the Commission in the Commission Documents.
Each of the Company and the Subsidiaries has in all material
respects performed all the obligations required to be performed by
them to date under the foregoing agreements, have received no
notice of default and are not in default under any Material
Agreement now in effect the result of which would cause a Material
Adverse Effect.
(u)
Transactions with Affiliates
.
Except as set forth in the Financial Statements or in the
Commission Documents, there are no loans, leases, agreements,
contracts, royalty agreements, management contracts or arrangements
or other continuing transactions between (a) the Company or any
Subsidiary on the one hand, and (b) on the other hand, any officer,
employee, consultant or director of the Company, or any of its
Subsidiaries, or any person owning any capital stock of the Company
or any Subsidiary or any member of the immediate family of such
officer, employee, consultant, director or stockholder or any
corporation or other entity controlled by such officer, employee,
consultant, director or stockholder, or a member of the immediate
family of such officer, employee, consultant, director or
stockholder.
(v)
Securities Act of 1933
.
Assuming the accuracy of the representations of the Purchasers set
forth in Section 3.2 hereof, the Company has complied with all
applicable federal and state securities laws in connection with the
offer, issuance and sale of the Securities hereunder. Neither the
Company nor anyone acting on its behalf, directly or indirectly,
has or will sell, offer to sell or solicit offers to buy any of the
Securities or similar securities to, or solicit offers with respect
thereto from, or enter into any preliminary conversations or
negotiations relating thereto with, any person, or has taken or
will take any action so as to bring the issuance and sale of any of
the Securities in violation of the registration provisions of the
Securities Act and applicable state securities laws, and neither
the Company nor any of its affiliates, nor any person acting on its
or their behalf, has engaged in any form of general solicitation or
general advertising (within the meaning of Regulation D under the
Securities Act) in connection with the offer or sale of any of the
shares of Common Stock.
(w)
Governmental Approvals
. Except
for the filing of any notice prior or subsequent to the Closing
Date that may be required under applicable state and/or federal
securities laws (which if required, shall be filed on a timely
basis), including the filing of a Form D, no authorization,
consent, approval, license, exemption of, filing or registration
with any court or governmental department, commission, board,
bureau, agency or instrumentality, domestic or foreign, is or will
be necessary for, or in connection with, the execution or delivery
of the Securities or for the performance by the Company of its
obligations under the Transaction Documents.
(x)
Employees
. Except as disclosed
on
Schedule 3.1(x
),
neither the Company nor any Subsidiary has any collective
bargaining arrangements covering any of its employees. Except as
disclosed in the Commission Documents,
Schedule 3.1(x)
sets forth a
list of the employment contracts, agreements regarding proprietary
information, non-competition agreements, non-solicitation
agreements, confidentiality agreement, or any other similar
contract or restrictive covenant, relating to the right of any
officer, employee or consultant to be employed or engaged by the
Company. Since February 28, 2017, no officer, consultant or key
employee of the Company or any Subsidiary whose termination, either
individually or in the aggregate, would have a Material Adverse
Effect, has terminated or, to the knowledge of the Company, has any
present intention of terminating his or her employment or
engagement with the Company or any Subsidiary.
(y)
Absence of Certain
Developments
. Except as disclosed on
Schedule 3.1(y)
, since February
28, 2017, neither the Company nor the Subsidiaries
have:
(i)
issued any stock,
bonds or other corporate securities or any rights, options or
warrants with respect thereto;
(ii)
borrowed
any amount or incurred or become subject to any liabilities
(absolute or contingent) except current liabilities incurred in the
ordinary course of business which are comparable in nature and
amount to the current liabilities incurred in the ordinary course
of business during the comparable portion of its prior fiscal year,
as adjusted to reflect the current nature and volume of the
Company’s or such Subsidiary’s business;
(iii)
discharged
or satisfied any Lien or paid any obligation or liability (absolute
or contingent), other than current liabilities paid in the ordinary
course of business;
(iv)
declared
or made any payment or distribution of cash or other Property to
stockholders with respect to its stock, or purchased or redeemed,
or made any agreements so to purchase or redeem, any shares of its
capital stock;
(v)
sold, assigned or
transferred any other tangible assets, or canceled any debts or
claims, except in the ordinary course of business;
(vi)
sold,
assigned or transferred any patent rights, trademarks, trade names,
copyrights, trade secrets or other intangible assets or
Intellectual Property Rights, or disclosed any proprietary
confidential information to any person except to customers in the
ordinary course of business or to the Purchasers or their
representatives;
(vii)
suffered
any substantial losses or waived any rights of material value,
whether or not in the ordinary course of business, or suffered the
loss of any material amount of prospective business;
(viii)
made
any changes in employee compensation except in the ordinary course
of business and consistent with past practices;
(ix)
made
capital expenditures or commitments therefor that aggregate in
excess of $100,000;
(x)
entered into any
other transaction other than in the ordinary course of business, or
entered into any other material transaction, whether or not in the
ordinary course of business;
(xi)
made
charitable contributions or pledges in excess of
$10,000;
(xii)
suffered
any material damage, destruction or casualty loss, whether or not
covered by insurance;
(xiii)
experienced
any material problems with labor or management in connection with
the terms and conditions of their employment;
(xiv)
effected
any two or more events of the foregoing kind which in the aggregate
would be material to the Company or its Subsidiaries;
or
(xv)
entered
into an agreement, written or otherwise, to take any of the
foregoing actions.
(z)
Investment Company Act
. The
Company is not, and is not an affiliate of, and immediately after
receipt of payment for the Securities, will not be or be an
affiliate of, an “investment company” within the
meaning of the Investment Company Act of 1940, as amended. The
Company shall conduct its business in a manner so that it will not
become an “investment company” subject to registration
under the Investment Company Act of 1940, as amended.
(aa)
No
Integrated Offering
. Neither the Company, nor any of its
affiliates, nor any person acting on its or their behalf, has
directly or indirectly made any offers or sales of any security or
solicited any offers to buy any security under circumstances that
would cause the offering and/or sale of the Securities pursuant to
this Agreement to be integrated with prior offerings by the Company
for purposes of the Securities Act which would prevent the Company
from selling the Securities pursuant to Rule 506 under the
Securities Act, nor will the Company or any of its affiliates take
any action or steps that would cause the Offering and/or sale of
the Securities to be integrated with other offerings.
(bb)
Sarbanes-Oxley
Act.
The Company is in compliance in all material respects
with the applicable provisions of the Sarbanes-Oxley Act of 2002
(the “
Sarbanes-Oxley
Act
”), and the rules and regulations promulgated
thereunder, that are effective and for which compliance by the
Company is required as of the date hereof. The Company has
established disclosure controls and procedures (as such term is
defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) for
the Company and designed such disclosure controls and procedures to
ensure that information required to be disclosed by the Company in
the reports it files or submits under the Exchange Act is recorded,
processed, summarized and reported, within the time periods
specified in the Commission’s rules and forms. The
Company’s certifying officers have evaluated the
effectiveness of the Company’s disclosure controls and
procedures as of the end of the period covered by the
Company’s most recently filed periodic report under the
Exchange Act (such date, the “
Evaluation Date
”). The
Company presented in its most recently filed periodic report under
the Exchange Act the conclusions of the certifying officers about
the effectiveness of the disclosure controls and procedures based
on their evaluations as of the Evaluation Date. Since the
Evaluation Date, there have been no changes in the Company’s
internal control over financial reporting (as such term is defined
in the Exchange Act) that has materially affected, or is reasonably
likely to materially affect, the Company’s internal control
over financial reporting.
(cc)
Shell
Company Status
. The Company is not currently an issuer
identified in Securities Act Rule 144(i)(1).
(dd)
Listing
and Maintenance Requirements
. The Common Stock is registered
pursuant to Section 12(g) of the Exchange Act, and the Company has
taken no action designed to, or which to its knowledge is likely to
have the effect of, terminating the registration of the Common
Stock under the Exchange Act nor has the Company received any
notification that the Commission is contemplating terminating such
registration. The Company has not, in the 12 months preceding the
date hereof, received notice from the OTCQB to the effect that the
Company is not in compliance with the listing or maintenance
requirements of the OTCQB. The Company is, and has no reason to
believe that it will not in the foreseeable future continue to be,
in compliance with all such listing and maintenance
requirements
(ee)
Use
of Proceeds
. Except as disclosed on
Schedule 3.1(ee)
, the Company
hereby covenants to use the net proceeds received from the Offering
to (i) repay $300,000 of the Promissory Note concurrent with the
Initial Closing, (ii) research and development activities primarily
related to the Company’s therapeutic and companion diagnostic
technologies, and (iii) for general corporate and working capital
purposes.
Section
3.2
Representations and Warranties of Each
of the Purchasers
. Each Purchaser, severally and not jointly
with the other Purchasers, hereby makes the following
representations and warranties to the Company as of the date
hereof, with respect solely to itself and not with respect to any
other Purchaser:
(a)
Organization and Good Standing of the
Purchasers
. If the Purchaser is an entity, such Purchaser is
a corporation, partnership or limited liability company duly
incorporated or organized, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or
organization.
(b)
Authorization and Power
. Such
Purchaser has the requisite power and authority to enter into and
perform this Agreement and each of the other Transaction Documents
to which such Purchaser is a party and to purchase the Securities,
being sold to it hereunder. The execution, delivery and performance
of this Agreement and each of the other Transaction Documents to
which such Purchaser is a party by such Purchaser and the
consummation by it of the transactions contemplated hereby and
thereby have been duly authorized by all necessary corporate,
partnership or limited liability company action, and no further
consent or authorization of such Purchaser or its Board of
Directors, stockholders, partners, members, or managers, as the
case may be, is required. This Agreement and each of the other
Transaction Documents to which such Purchaser is a party has been
duly authorized, executed and delivered by such Purchaser and
constitutes, or shall constitute when executed and delivered, a
valid and binding obligation of such Purchaser enforceable against
such Purchaser in accordance with the terms hereof, except as such
enforceability may be limited by applicable bankruptcy, insolvency,
reorganization, moratorium, liquidation, conservatorship,
receivership or similar laws relating to, or affecting generally
the enforcement of, creditor’s rights and remedies or by
other equitable principles of general application.
(c)
No Conflicts
. Such Purchaser is
not required to obtain any consent, authorization or order of, or
make any filing or registration with, any court or governmental
agency in order for it to execute, deliver or perform any of its
obligations under this Agreement or any other Transaction Document
to which such Purchaser is a party or to purchase the Securities in
accordance with the terms hereof, provided, that for purposes of
the representation made in this sentence, such Purchaser is
assuming and relying upon the accuracy of the relevant
representations and agreements of the Company herein.
(d)
Status of Purchasers
. Such
Purchaser is an “accredited investor” as defined in
Regulation D under the Securities Act and as set forth on the
questionnaire (the “
Confidential Private Purchaser
Questionnaire
”) attached hereto as
Exhibit F
and made part hereof.
Such Purchaser is not required to be registered as a broker-dealer
under Section 15 of the Exchange Act and such Purchaser is not a
broker-dealer, nor an affiliate of a broker-dealer, unless
indicated on such Confidential Private Purchaser
Questionnaire.
(e)
Acquisition for Investment
.
Such Purchaser is acquiring the Securities solely for its own
account for the purpose of investment and not with a view to or for
sale in connection with a distribution. Such Purchaser does not
have a present intention to sell the Securities, nor a present
arrangement (whether or not legally binding) or intention to effect
any distribution of the Securities to or through any person or
entity;
provided
,
however
, that by
making the representations herein, such Purchaser does not agree to
hold the Securities for any minimum or other specific term and
reserves the right to dispose of the Securities at any time in
accordance with federal and state securities laws applicable to
such disposition. Each Purchaser acknowledges that it is able to
bear the financial risks associated with an investment in the
Securities and that it has been given full access to such records
of the Company and to the officers of the Company and received such
information as it has deemed necessary or appropriate to conduct
its due diligence investigation and has sufficient knowledge and
experience in investing in companies similar to the Company in
terms of the Company’s stage of development so as to be able
to evaluate the risks and merits of its investment in the
Company.
(f)
Opportunities for Additional
Information
. Such Purchaser acknowledges that such Purchaser
has had the opportunity to ask questions of and receive answers
from, or obtain additional information from, the executive officers
of the Company concerning the financial and other affairs of the
Company. Such Purchaser acknowledges and agrees that neither the
Agent nor any Affiliate of the Agent has provided such Purchaser
with any information or advice with respect to the Securities nor
is such information or advice necessary or desired. Neither the
Agent nor any Affiliate thereof has made or makes any
representation as to the Company or the quality of the Securities
and the Agent and any Affiliate thereof may have acquired
non-public information with respect to the Company which such
Purchaser agrees need not be provided to it. In connection with the
issuance of the Securities to such Purchaser, neither the Agent nor
any of its Affiliates has acted as a financial advisor or fiduciary
to such Purchaser.
(g)
No General Solicitation
. Such
Purchaser acknowledges that the Securities were not offered to such
Purchaser by means of any form of general or public solicitation or
general advertising, or publicly disseminated advertisements or
sales literature, including (i) any advertisement, article, notice
or other communication published in any newspaper, magazine, or
similar media, or broadcast over television or radio, or (ii) any
seminar or meeting to which such Purchaser was invited by any of
the foregoing means of communications.
(h)
Rule 144
. Such Purchaser
understands that the Notes, Note Warrants, and Warrant Shares must
be held indefinitely unless such Notes, Note Warrants, and Warrant
Shares are registered under the Securities Act or an exemption from
registration is available. Such Purchaser acknowledges that such
Purchaser is familiar with Rule 144 and that such person has been
advised that Rule 144 permits resales only under certain
circumstances. Such Purchaser understands that to the extent that
Rule 144 is not available, such Purchaser may be unable to sell any
Notes, Note Warrants, and Warrant Shares without either
registration under the Securities Act or the existence of another
exemption from such registration requirement.
(i)
General
. Such Purchaser
understands that the Securities are being offered and sold in
reliance on a transactional exemption from the registration
requirements of federal and state securities laws and the Company
is relying upon the truth and accuracy of the representations,
warranties, agreements, acknowledgments and understandings of such
Purchaser set forth herein in order to determine the applicability
of such exemptions and the suitability of such Purchaser to acquire
the Securities.
(j)
Independent Investment
. Except
as may be disclosed in any filings with the Commission by the
Purchasers under Section 13 and/or Section 16 of the Exchange Act,
no Purchaser has agreed to act with any other Purchaser for the
purpose of acquiring, holding, voting or disposing of the
Securities purchased hereunder for purposes of Section 13(d) under
the Exchange Act, and each Purchaser is acting independently with
respect to its investment in the Securities.
(k)
Certain Fees
. Except as set
forth on
Schedule
3.1(q)
hereto, each Purchaser has no knowledge (without any
investigation or due inquiry) of any brokers fees, finders’
fees or financial advisory fees or commissions payable by the
Company with respect to the transactions contemplated by this
Agreement and the other Transaction Documents.
(l)
No Short Sales
. The Purchaser
has not directly or indirectly, nor has any Person acting on behalf
of or pursuant to any understanding with such Purchaser, executed
any Short Sales (as defined below), of the securities of the
Company during the period commencing as of the time that such
Purchaser first received a term sheet (written or oral) from the
Company or any Agent representing the Company setting forth the
material terms of the transactions contemplated by this Agreement
and ending immediately following the public dissemination of the
Press Release (as defined below).
(m)
Lock-Up
. Each Purchaser hereby
agrees with the Company that such Purchaser will not offer, sell,
or contract to sell any of the Company’s securities and/or
shares of Common Stock that it or its affiliates beneficially owns
(currently or acquires in the future) (the “
Lock-Up Shares
”) on a
national exchange or in the public marketplace for a period
commencing on the Initial Closing Date through December 31, 2018
(the “
Lock-Up
Period
”). Furthermore, if at the expiration of the
Lock-Up Period, the Company delivers a notice, pursuant to Section
4.3, to the Purchaser on or prior to the expiration of the Lock-Up
Period (the “
Extension Notice
”),
indicating that the Company is actively negotiating private or
public offering of equity or equity-linked securities (the
“
Qualified
Offering
”), then the restrictions of this Section
3.2(m) shall automatically be extended to the earlier of (i) ninety
(90) days following the expiration of the Lock-Up Period, or (ii)
the filing of a Form 8-K with the Commission disclosing the closing
of the Qualified Offering (the “
Extension Period
”).
During the Lock-Up Period and Extension Period (if any), the
Purchaser may offer, sell, or contract to sell, whether in whole or
in part, the Lock-Up Shares in a privately negotiated transaction
with a third party (the “
Third-Party Purchaser
”),
provided
,
however
, that the
Third-Party Purchaser enters into a similar lock-up agreement with
the Company.
ARTICLE IV
Covenants
The
Company covenants with each of the Purchasers as follows, which
covenants are for the benefit of the Purchasers and their permitted
assignees (as defined herein).
Section
4.1
Securities Compliance
. The
Company shall notify the Commission in accordance with its rules
and regulations, of the transactions contemplated by any of the
Transaction Documents, including filing a Form D with respect to
the Securities as required under Regulation D and applicable
“blue sky” laws, and shall take all other necessary
action and proceedings as may be required and permitted by
applicable law, rule and regulation, for the legal and valid
issuance of the Securities to the Purchasers or subsequent
holders.
Section
4.2
Compliance with Laws
. The
Company shall comply, and cause each Subsidiary to comply in all
respects, with all applicable laws, rules, regulations and orders,
except for such non-compliance which singularly or in the aggregate
could not reasonably be expected to have a Material Adverse
Effect.
Section
4.3
Keeping of Records and Books of
Account
. The Company shall keep and cause each Subsidiary to
keep adequate records and books of account, in which complete
entries will be made in accordance with U.S. GAAP consistently
applied, reflecting all financial transactions of the Company and
each Subsidiary.
Section
4.4
Reservation of Shares
. So long
as any of the Note Warrants remain outstanding, the Company shall
take all action necessary to at all times have authorized, and
reserved for the purpose of issuance, a sufficient number of shares
of Common Stock needed to provide for the issuance of the Warrant
Shares.
Section
4.5
Disclosure of Transaction
. The
Company shall issue a press release describing the material terms
of the transactions contemplated hereby (the “
Press Release
”) as soon
as practicable after the Initial Closing. The Company shall also
file with the Commission, a Current Report on Form 8-K describing
the material terms of the transactions contemplated hereby (and
attaching as exhibits thereto this Agreement and other Transaction
Documents) within four (4) Business Days following the Initial
Closing.
Section
4.6
Disclosure of Material
Information
. The Company and the Subsidiaries covenant and
agree that neither it nor any other person acting on its or their
behalf has provided or, from and after the filing of the Press
Release, will provide any Purchaser or its agents or counsel with
any information that the Company believes constitutes material
non-public information (other than with respect to the transactions
contemplated by this Agreement), unless prior thereto such
Purchaser shall have executed a specific written agreement
regarding the confidentiality and use of such information. The
Company understands and confirms that each Purchaser shall be
relying on the foregoing covenants in effecting transactions in
securities of the Company. Unless otherwise agreed to by the
applicable parties, at the time of the filing of the Press Release,
no Purchaser shall be in possession of any material, nonpublic
information received from the Company, any of its Subsidiaries or
any of its respective officers, directors, employees or agents,
that is not disclosed in the Press Release. The Company shall not
disclose the identity of any Purchaser in any filing with the
Commission except as required by the rules and regulations of the
Commission thereunder.
Section
4.7
Pledge of Securities
. The
Company acknowledges and agrees that the Securities may be pledged
by a Purchaser in connection with a
bona
fide
margin agreement or other
loan or financing arrangement that is secured by the Securities.
The pledge of the Securities shall not be deemed to be a transfer,
sale or assignment of the Securities hereunder, and no Purchaser
effecting a pledge of the Securities shall be required to provide
the Company with any notice thereof or otherwise make any delivery
to the Company pursuant to this Agreement or any other Transaction
Document;
provided
,
that a Purchaser and its pledgee shall be required to comply with
the provisions of Article VI hereof in order to effect a sale,
transfer or assignment of Securities to such pledgee. At a
Purchaser’s expense, the Company hereby agrees to execute and
deliver such documentation as a pledgee of the Securities may
reasonably request in connection with a pledge of the Securities to
such pledgee by a Purchaser, in accordance with applicable laws
relating to the transfer of the securities.
Section
4.8
No Integrated Offerings
. The
Company shall not make any offers or sales of any security (other
than the Securities being offered or sold hereunder) under
circumstances that would require registration of the Securities
being offered or sold hereunder under the Securities
Act.
Section
4.9
SEC Reports
. Until the time
that no Purchaser owns Securities, the Company covenants to
maintain the registration of the Common Stock under Section 12(b)
or 12(g) of the Exchange Act and to timely file (or obtain
extensions in respect thereof and file within the applicable grace
period) all reports required to be filed by the Company after the
date hereof pursuant to the Exchange Act even if the Company is not
then subject to the reporting requirements of the Exchange
Act.
ARTICLE V
CONDITIONS
Section
5.1
Conditions Precedent to the Obligation
of the Company to Sell the Securities
. The obligation
hereunder of the Company to issue and sell the Securities to the
Purchasers is subject to the satisfaction or waiver, at or before
each Closing, of each of the conditions set forth below. These
conditions are for the Company’s sole benefit and may be
waived by the Company at any time in its sole
discretion.
(a)
Accuracy of Each Purchaser’s
Representations and Warranties
. Each of the representations
and warranties of each Purchaser in this Agreement and the other
Transaction Documents that are qualified by materiality or by
reference to any Material Adverse Effect shall be true and correct
in all respects, and all other representations and warranties shall
be true and correct in all material respects, as of the date when
made and as of the Closing Date as though made at that time, except
for representations and warranties that are expressly made as of a
particular date, which shall be true and correct in all respects as
of such date.
(b)
Performance by the Purchasers
.
Each Purchaser shall have performed, satisfied and complied in all
respects with all covenants, agreements and conditions required by
this Agreement to be performed, satisfied or complied with by such
Purchaser at or prior to the Closing.
(c)
No Injunction
. No statute,
rule, regulation, executive order, decree, ruling or injunction
shall have been enacted, entered, promulgated or endorsed by any
court or governmental authority of competent jurisdiction which
prohibits the consummation of any of the transactions contemplated
by this Agreement.
(d)
Delivery of Purchase Price
. The
Purchase Price for the Securities being paid for in cash shall have
been delivered to the Escrow Account in accordance with the
instructions provided herein.
(e)
Delivery of Transaction
Documents
. The Transaction Documents to which the Purchasers
are parties shall have been duly executed and delivered by the
Purchasers to the Company.
Section
5.2
Conditions Precedent to the Obligation
of the Purchasers to Purchase the Shares
. The obligation
hereunder of each Purchaser to acquire and pay for the Securities
is subject to the satisfaction or waiver, at or before each
Closing, of each of the conditions set forth below. These
conditions are for each Purchaser’s sole benefit and may be
waived by such Purchaser at any time in its sole
discretion.
(a)
Accuracy of the Company’s
Representations and Warranties
. Each of the representations
and warranties of the Company in this Agreement and the other
Transaction Documents that are qualified by materiality or by
reference to any Material Adverse Effect shall be true and correct
in all respects, and all other representations and warranties shall
be true and correct in all material respects, as of the date when
made and as of the Closing Date as though made at that time, except
for representations and warranties that are expressly made as of a
particular date, which shall be true and correct in all respects as
of such date.
(b)
Performance by the Company
. The
Company shall have performed, satisfied and complied in all
respects with all covenants, agreements and conditions required by
this Agreement to be performed, satisfied or complied with by the
Company at or prior to the Closing.
(c)
Necessary Consents
. The Company
shall have received all necessary consents to perform the
transaction contemplated by this Agreement and the Transaction
Documents.
(d)
No Injunction
. No statute,
rule, regulation, executive order, decree, ruling or injunction
shall have been enacted, entered, promulgated or endorsed by any
court or governmental authority of competent jurisdiction which
prohibits the consummation of any of the transactions contemplated
by this Agreement.
(e)
No Proceedings or Litigation
.
No action, suit or proceeding before any arbitrator or any
governmental authority shall have been commenced, and no
investigation by any governmental authority shall have been
threatened, against the Company or any Subsidiary, or any of the
officers, directors or affiliates of the Company or any Subsidiary
seeking to restrain, prevent or change the transactions
contemplated by this Agreement, or seeking damages in connection
with such transactions.
(f)
Certificates
. Promptly
following each Closing, the Company shall deliver to the Purchasers
the certificates for the Notes and the Note Warrants being acquired
by such Purchaser at the Closing to such address set forth next to
each Purchaser’s name on
Exhibit A
attached hereto with
respect to such Closing.
(g)
Resolutions
. The Board of
Directors of the Company shall have adopted resolutions consistent
with Section 3.1(b) hereof in a form reasonably acceptable to such
Purchaser.
(h)
No Suspensions of Trading in Common
Stock
. The Common Stock shall not have been suspended, as of
the Closing Date, by the Commission or the OTCQB from trading on
the OTCQB nor shall suspension by the Commission or the OTCQB have
been threatened, as of the Closing Date, either (A) in writing by
the Commission or the OTCQB or (B) by falling below the minimum
listing maintenance requirements of the OTCQB.
(i)
Officer’s Certificate
.
The Company shall have delivered to the Purchasers a certificate of
an executive officer of the Company, dated as of each Closing Date,
confirming the accuracy of the Company’s representations,
warranties and covenants as of each Closing Date and confirming the
compliance by the Company with the conditions precedent set forth
in this Section 5.2 as of each Closing Date.
(j)
Delivery of Transaction
Documents
. The Transaction Documents to which the Company is
a party shall have been duly executed and delivered by the Company
to the Purchasers.
(k)
Legal Opinions
. The Purchasers
shall have received opinions, each dated as of Closing Date, from
Loeb & Loeb, LLP and Sherman & Howard LLC, in form and
substance satisfactory to the Purchasers.
ARTICLE VI
Stock Certificate Legend
Section
6.1
Legend
.
(a)
The Securities may
only be disposed of in compliance with state and federal securities
laws. In connection with any transfer of Securities other than
pursuant to an effective registration statement or Rule 144, to the
Company or to an affiliate of a Purchaser or in connection with a
pledge as contemplated in Section 4.7, the Company may require the
transferor thereof to provide to the Company an opinion of counsel
selected by the transferor and reasonably acceptable to the
Company, the form and substance of which opinion shall be
reasonably satisfactory to the Company, to the effect that such
transfer does not require registration of such transferred
Securities under the Securities Act. As a condition of transfer,
any such transferee shall agree in writing to be bound by the terms
of this Agreement and shall have the rights and obligations of a
Purchaser under this Agreement.
(b)
Each certificate
representing the Securities shall be stamped or otherwise imprinted
with a legend substantially in the following form (in addition to
any legend required by applicable state securities or “blue
sky” laws):
“THIS
SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE
COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE
UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF
1933, AS AMENDED (THE “SECURITIES ACT”), AND,
ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN
EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR
PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT
SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND
IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY
MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A
REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION
THAT IS AN “ACCREDITED INVESTOR” AS DEFINED IN RULE
501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH
SECURITIES.”
(c)
The Company
acknowledges and agrees that a Purchaser may from time to time
pledge pursuant to a bona fide margin agreement with a registered
broker-dealer or grant a security interest in some or all of the
Securities to a financial institution that is an “accredited
investor” as defined in Rule 501(a) under the Securities Act
and who agrees to be bound by the provisions of this Agreement and,
if required under the terms of such arrangement, such Purchaser may
transfer pledged or secured Securities to the pledgees or secured
parties. Such a pledge or transfer would not be subject to approval
of the Company and no legal opinion of legal counsel of the
pledgee, secured party or pledgor shall be required in connection
therewith. Further, no notice shall be required of such pledge. At
the appropriate Purchaser’s expense, the Company will execute
and deliver such reasonable documentation as a pledgee or secured
party of Securities may reasonably request in connection with a
pledge or transfer of the Securities, including, if the Securities
are subject to registration, the preparation and filing of any
required prospectus supplement under Rule 424(b)(3) under the
Securities Act or other applicable provision of the Securities Act
to appropriately amend the list of selling stockholders
thereunder.
(d)
So long as the
Company has received written representations from such Purchaser as
reasonably requested by the Company in connection with such legend
removal (which shall not include representations with respect to
the sale of any securities), certificates evidencing the Notes and
Warrant Shares shall not contain any legend (including the legend
set forth in Section 6.1(b) hereof), (i) while a registration
statement covering the resale of such security is effective under
the Securities Act, (ii) following any sale of such Notes and
Warrant Shares pursuant to Rule 144, (iii) if such Notes and
Warrant Shares are eligible for sale under Rule 144, or (iv) if
such legend is not required under applicable requirements of the
Securities Act (including judicial interpretations and
pronouncements issued by the staff of the Commission). The Company
shall cause its counsel to issue a legal opinion to its transfer
agent promptly after the effective date of any registration
statement filed in connection with this Agreement if required by
its transfer agent to effect the removal of the legend hereunder,
subject to the Company receiving written representations from such
Purchaser as reasonably requested by the Company in connection with
such legend removal (which shall not include representations with
respect to the sale of any securities). If such Notes and Warrant
Shares may be sold under Rule 144 and the Company is then in
compliance with the current public information required under Rule
144, or if the Notes and Warrant Shares may be sold under Rule 144
without the requirement for the Company to be in compliance with
the current public information required under Rule 144 as to such
Notes and Warrant Shares or if such legend is not otherwise
required under applicable requirements of the Securities Act
(including judicial interpretations and pronouncements issued by
the staff of the Commission) then such Notes and Warrant Shares
shall be issued free of all legends, subject to the Company
receiving written representations from such Purchaser as reasonably
requested by the Company in connection with such legend removal
(which shall not include representations with respect to the sale
of any securities). The Company agrees that following the effective
date of any registration statement filed in connection with this
Agreement or at such time as such legend is no longer required
under this Section 6.1(d), it will, no later than three Trading
Days following the delivery by a Purchaser to the Company or its
transfer agent of a certificate representing Notes and Warrant
Shares, as the case may be, issued with a restrictive legend (such
third Trading Day, the “
Legend Removal Date
”),
deliver or cause to be delivered to such Purchaser a certificate
representing such shares that is free from all restrictive and
other legends, subject to the Company receiving written
representations from such Purchaser as reasonably requested by the
Company in connection with such legend removal (which shall not
include representations with respect to the sale of any
securities). The Company may not make any notation on its records
or give instructions to the transfer agent that enlarge the
restrictions on transfer set forth in this Section 6.1(d).
Certificates for Securities subject to legend removal hereunder
shall be transmitted by the transfer agent to the Purchaser by
crediting the account of the Purchaser’s prime broker with
the Depository Trust Company System as directed by such
Purchaser.
(e)
In addition to such
Purchaser’s other available remedies, subject to the Company
receiving written representations from such Purchaser as reasonably
requested by the Company in connection with such legend removal
(which shall not include representations with respect to the sale
of any securities), the Company shall pay to a Purchaser, in cash,
if the Company fails to (i) issue and deliver (or cause to be
delivered) to a Purchaser by the Legend Removal Date a certificate
representing the Securities so delivered to the Company by such
Purchaser that is free from all restrictive and other legends or
(ii) if after the Legend Removal Date such Purchaser purchases (in
an open market transaction or otherwise) shares of Common Stock to
deliver in satisfaction of a sale by such Purchaser of all or any
portion of the number of shares of Common Stock, or a sale of a
number of shares of Common Stock equal to all or any portion of the
number of shares of Common Stock that such Purchaser anticipated
receiving from the Company without any restrictive legend, then, an
amount equal to the excess of such Purchaser’s total purchase
price (including brokerage commissions and other out-of-pocket
expenses, if any) for the shares of Common Stock so purchased
(including brokerage commissions and other out-of-pocket expenses,
if any) (the “
Buy-In
Price
”) over the product of (A) such number of
Underlying Shares that the Company was required to deliver to such
Purchaser by the Legend Removal Date multiplied by (B) the lowest
closing sale price of the Common Stock on any Trading Day during
the period commencing on the date of the delivery by such Purchaser
to the Company of the applicable Securities (as the case may be)
and ending on the date of such delivery and payment under this
clause (ii).
(f)
Each Purchaser,
severally and not jointly with the other Purchasers, agrees with
the Company that such Purchaser will sell any Securities pursuant
to either the registration requirements of the Securities Act,
including any applicable prospectus delivery requirements, or an
exemption therefrom, and that if Securities are sold pursuant to a
registration statement, they will be sold in compliance with the
plan of distribution set forth therein, and acknowledges that the
removal of the restrictive legend from certificates representing
Securities as set forth in this Section 6.1(f) is predicated upon
the Company’s reliance upon this understanding and is subject
to the Company receiving written representations from such
Purchaser as reasonably requested by the Company in connection with
such legend removal (which shall not include representations with
respect to the sale of any securities).
(g)
At any time during
the period commencing from the six (6) month anniversary of the
date of this Agreement, if the Company shall fail for any reason to
satisfy the current public information requirements under Rule
144(c) (a “
Public
Information Failure
”), then, in addition to each
Purchaser’s other available remedies, the Company shall pay
to each Purchaser, in cash, as partial liquidated damages and not
as a penalty, by reason of any such delay in or reduction of its
ability to sell the Securities, an amount in cash equal to one
quarter of one percent (0.25%) of the aggregate Purchase Price of
each such Purchaser’s Securities on the day of a Public
Information Failure and such amount on each day thereafter until
the date such Public Information Failure is cured. The payments to
which a Purchaser shall be entitled pursuant to this Section 6.1(g)
are referred to herein as “
Public Information Failure
Payments
.” For purposes hereof, a “Public
Information Failure” shall not be deemed to have occurred or
be continuing during any Rule 12b-25 extension period for any
annual, quarterly or other report required to be filed by the
Company with the Commission unless a Purchaser is not permitted to
sell Common Stock pursuant to Rule 144, counsel for the Company
will not provide any required Rule 144 legal opinions, or an
effective registration statement is not available during such
extension period. Public Information Failure Payments shall be paid
on the earlier of (i) the last day of the calendar month during
which such Public Information Failure Payments are incurred, and
(ii) the third (3rd) Business Day after the event or failure giving
rise to the Public Information Failure Payments is cured. In the
event the Company fails to make Public Information Failure Payments
in a timely manner, such Public Information Failure Payments shall
bear interest at the rate of one half of one percent (0.50%) per
month (prorated for partial months) until paid in full. Nothing
herein shall limit such Purchaser’s right to pursue actual
damages for the Public Information Failure, and such Purchaser
shall have the right to pursue all remedies available to it at law
or in equity including, without limitation, a decree of specific
performance and/or injunctive relief.
ARTICLE VII
Indemnification
Section
7.1
General Indemnity
. The Company
agrees to indemnify and hold harmless the Purchasers (and their
respective directors, officers, managers, partners, members,
shareholders, affiliates, agents, successors and assigns) from and
against any and all losses, liabilities, deficiencies, costs,
damages and expenses (including, without limitation, reasonable
attorneys’ fees, charges and disbursements) incurred by the
Purchasers as a result of any breach of the representations,
warranties or covenants made by the Company herein. In no event
shall any Indemnified Party (as defined below) be entitled to
recover consequential or punitive damages resulting from a breach
or violation of this Agreement.
Section
7.2
Indemnification Procedure
. Any
party entitled to indemnification under this Article VII (an
“
Indemnified
Party
”) will give written notice to the indemnifying
party of any matters giving rise to a claim for indemnification;
provided
, that the
failure of any party entitled to indemnification hereunder to give
notice as provided herein shall not relieve the indemnifying party
of its obligations under this Article VII except to the extent that
the indemnifying party is actually prejudiced by such failure to
give notice. In case any action, proceeding or claim is brought
against an Indemnified Party in respect of which indemnification is
sought hereunder, the indemnifying party shall be entitled to
participate in and, unless in the reasonable judgment of the
Indemnified Party a conflict of interest between it and the
indemnifying party may exist with respect of such action,
proceeding or claim, to assume the defense thereof with counsel
reasonably satisfactory to the Indemnified Party. In the event that
the indemnifying party advises an Indemnified Party that it will
contest such a claim for indemnification hereunder, or fails,
within thirty (30) days of receipt of any indemnification notice to
notify, in writing, such person of its election to defend, settle
or compromise, at its sole cost and expense, any action, proceeding
or claim (or discontinues its defense at any time after it
commences such defense), then the Indemnified Party may, at its
option, defend, settle or otherwise compromise or pay such action
or claim. In any event, unless and until the indemnifying party
elects in writing to assume and does so assume the defense of any
such claim, proceeding or action, the Indemnified Party’s
costs and expenses arising out of the defense, settlement or
compromise of any such action, claim or proceeding shall be losses
subject to indemnification hereunder. The Indemnified Party shall
cooperate fully with the indemnifying party in connection with any
negotiation or defense of any such action or claim by the
indemnifying party and shall furnish to the indemnifying party all
information reasonably available to the Indemnified Party, which
relates to such action or claim. The indemnifying party shall keep
the Indemnified Party fully apprised at all times as to the status
of the defense or any settlement negotiations with respect thereto.
If the indemnifying party elects to defend any such action or
claim, then the Indemnified Party shall be entitled to participate
in such defense with counsel of its choice at its sole cost and
expense. The indemnifying party shall not be liable for any
settlement of any action, claim or proceeding effected without its
prior written consent,
provided
,
however
, that the indemnifying
party shall be liable for any settlement if the indemnifying party
is advised of the settlement but fails to respond to the settlement
within thirty (30) days of receipt of such notification.
Notwithstanding anything in this Article VII to the contrary, the
indemnifying party shall not, without the Indemnified Party’s
prior written consent, settle or compromise any claim or consent to
entry of any judgment in respect thereof which imposes any future
obligation on the Indemnified Party or which does not include, as
an unconditional term thereof, the giving by the claimant or the
plaintiff to the Indemnified Party of a release from all liability
in respect of such claim. The indemnity agreements contained herein
shall be in addition to (a) any cause of action or similar rights
of the Indemnified Party against the indemnifying party or others,
and (b) any liabilities the indemnifying party may be subject to
pursuant to the law.
ARTICLE VIII
Miscellaneous
Section
8.1
Fees and Expenses
. Except as
otherwise set forth in this Agreement and the other Transaction
Documents, each party shall pay the fees and expenses of its
advisors, counsel, accountants and other experts, if any, and all
other expenses, incurred by such party incident to the negotiation,
preparation, execution, delivery and performance of this
Agreement.
Section
8.2
Specific Enforcement; Consent to
Jurisdiction
.
(a)
The Company and the
Purchasers acknowledge and agree that irreparable damage may occur
in the event that any of the provisions of this Agreement or the
other Transaction Documents were not performed in accordance with
their specific terms or were otherwise breached. It is accordingly
agreed that the parties may be entitled to an injunction or
injunctions to prevent or cure breaches of the provisions of this
Agreement or the other Transaction Documents and to enforce
specifically the terms and provisions hereof or thereof, this being
in addition to any other remedy to which any of them may be
entitled by law or equity.
(b)
Each of the Company
and the Purchasers (i) hereby irrevocably submits to the exclusive
jurisdiction of the United States District Court sitting in the
Southern District of New York and the courts of the State of New
York located in New York county for the purposes of any suit,
action or proceeding arising out of or relating to this Agreement
or any of the other Transaction Documents or the transactions
contemplated hereby or thereby and (ii) hereby waives, and agrees
not to assert in any such suit, action or proceeding, any claim
that it is not personally subject to the jurisdiction of such
court, that the suit, action or proceeding is brought in an
inconvenient forum or that the venue of the suit, action or
proceeding is improper. Each of the Company and the Purchasers
consents to process being served in any such suit, action or
proceeding by mailing a copy thereof via registered or certified
mail or overnight delivery (with evidence of delivery) to such
party at the address in effect for notices to it under this
Agreement and agrees that such service shall constitute good and
sufficient service of process and notice thereof. Nothing in this
Section 8.2 shall affect or limit any right to serve process in any
other manner permitted by law. Each party hereby irrevocably waives
personal service of process and consents to process being served in
any such suit, action or proceeding by mailing a copy thereof to
such party at the address for such notices to it under this
Agreement and agrees that such service shall constitute good and
sufficient service of process and notice thereof. Nothing contained
herein shall be deemed to limit in any way any right to serve
process in any manner permitted by law.
Section
8.3
Entire Agreement; Amendment
.
This Agreement and the other Transaction Documents contains the
entire understanding and agreement of the parties with respect to
the matters covered hereby and, except as specifically set forth
herein or in the Transaction Documents, neither the Company nor any
of the Purchasers makes any representations, warranty, covenant or
undertaking with respect to such matters and they supersede all
prior understandings and agreements with respect to said subject
matter, all of which are merged herein. No provision of this
Agreement may be waived or amended other than by a written
instrument signed by the Company and the holders of over fifty
percent (50%) of the Notes then outstanding (the
“
Majority
Holders
”), and no provision hereof may be waived other
than by a written instrument signed by the party against whom
enforcement of any such waiver is sought. No such amendment shall
be effective to the extent that it applies to less than all of the
holders of the Shares then outstanding. No consideration shall be
offered or paid to any person to amend or consent to a waiver or
modification of any provision of any of this Agreement unless the
same consideration is also offered to all of the parties to this
Agreement.
Section
8.4
Notices
. Any and all notices or
other communications or deliveries required or permitted to be
provided hereunder shall be in writing and shall be deemed given
and effective on the earliest of: (a) the date of transmission, if
such notice or communication is delivered via electronic mail
(“
Email
”) at the Email
address set forth on the signature pages attached hereto at or
prior to 5:30 p.m. (New York City time) on a Trading Day, (b) the
next Trading Day after the date of transmission, if such notice or
communication is delivered via Email at the Email address set forth
on the signature pages attached hereto on a day that is not a
Trading Day or later than 5:30 p.m. (New York City time) on any
Trading Day, (c) the second (2
nd
) Trading Day
following the date of mailing, if sent by U.S. nationally
recognized overnight courier service or (d) upon actual receipt by
the party to whom such notice is required to be given. The address
for such notices and communications shall be as set forth on the
signature pages attached hereto.
Section
8.5
Waivers
. No waiver by any party
of any default with respect to any provision, condition or
requirement of this Agreement shall be deemed to be a continuing
waiver in the future or a waiver of any other provisions, condition
or requirement hereof, nor shall any delay or omission of any party
to exercise any right hereunder in any manner impair the exercise
of any such right accruing to it thereafter.
Section
8.6
Headings
. The section headings
contained in this Agreement (including, without limitation, section
headings and headings in the exhibits and schedules) are inserted
for reference purposes only and shall not affect in any way the
meaning, construction or interpretation of this Agreement. Any
reference to the masculine, feminine, or neuter gender shall be a
reference to such other gender as is appropriate. References to the
singular shall include the plural and vice versa.
Section
8.7
Successors and Assigns
. This
Agreement may not be assigned by a party hereto without the prior
written consent of the Company or the Purchasers, as applicable,
provided
,
however
, that,
subject to federal and state securities laws and as otherwise
provided in the Transaction Documents, a Purchaser may assign its
rights and delegate its duties hereunder in whole or in part (i) to
a third party acquiring all or substantially all of its Securities
in a private transaction or (ii) to an affiliate, in each case,
without the prior written consent of the Company or the other
Purchasers, after notice duly given by such Purchaser to the
Company
provided
,
that no such assignment or obligation shall affect the obligations
of such Purchaser hereunder and that such assignee agrees in
writing to be bound, with respect to the transferred securities, by
the provisions hereof that apply to the Purchasers. The provisions
of this Agreement shall inure to the benefit of and be binding upon
the respective permitted successors and assigns of the parties.
Nothing in this Agreement, express or implied, is intended to
confer upon any party other than the parties hereto or their
respective successors and assigns any rights, remedies, obligations
or liabilities under or by reason of this Agreement, except as
expressly provided in this Agreement.
Section
8.8
No Third Party Beneficiaries
.
The Agent shall be the third party beneficiary of the
representations and warranties of the Company in Section 3.1 and
the representations and warranties of the Purchasers in Section
3.2. This Agreement is intended for the benefit of the parties
hereto and their respective successors and permitted assigns and is
not for the benefit of, nor may any provision hereof be enforced
by, any other Person, except as otherwise set forth in Article VII
and this Section 8.8.
Section
8.9
Governing Law
. This Agreement
shall be governed by and construed in accordance with the internal
laws of the State of New York, without giving effect to any of the
conflicts of law principles which would result in the application
of the substantive law of another jurisdiction. This Agreement
shall not be interpreted or construed with any presumption against
the party causing this Agreement to be drafted.
Section
8.10
Survival
. The representations
and warranties of the Company and the Purchasers shall survive the
execution and delivery hereof and the Closing hereunder for a
period of eighteen (18) month following the Closing
Date.
Section
8.11
Counterparts
. This Agreement
may be executed in any number of counterparts, each of which when
so executed shall be deemed to be an original and, all of which
taken together shall constitute one and the same Agreement and
shall become effective when counterparts have been signed by each
party and delivered to the other parties hereto, it being
understood that all parties need not sign the same counterpart. In
the event that any signature is delivered by facsimile
transmission, such signature shall create a valid binding
obligation of the party executing (or on whose behalf such
signature is executed) the same with the same force and effect as
if such facsimile signature were the original thereof.
Section
8.12
Publicity
. The Company agrees
that it will not disclose, and will not include in any public
announcement, the name of the Purchasers without the consent of the
Purchasers unless and until such disclosure is required by law or
applicable regulation, and then only to the extent of such
requirement.
Section
8.13
Severability
. If any term,
provision, covenant or restriction of this Agreement is held by a
court of competent jurisdiction to be invalid, illegal, void or
unenforceable, the remainder of the terms, provisions, covenants
and restrictions set forth herein shall remain in full force and
effect and shall in no way be affected, impaired or invalidated,
and the parties hereto shall use their commercially reasonable
efforts to find and employ an alternative means to achieve the same
or substantially the same result as that contemplated by such term,
provision, covenant or restriction. It is hereby stipulated and
declared to be the intention of the parties that they would have
executed the remaining terms, provisions, covenants and
restrictions without including any of such that may be hereafter
declared invalid, illegal, void or unenforceable.
Section
8.14
Further Assurances
. From and
after the date of this Agreement, upon the request of any Purchaser
or the Company, each of the Company and the Purchasers shall
execute and deliver such instrument, documents and other writings
as may be reasonably necessary or desirable to confirm and carry
out and to effectuate fully the intent and purposes of this
Agreement, the Notes, the Note Warrants, the Warrant Shares, and
the other Transaction Documents.
Section
8.15
Independent Nature of
Purchasers’ Obligations and Rights
. The obligations of
each Purchaser under any Transaction Document are several and not
joint with the obligations of any other Purchaser, and no Purchaser
shall be responsible in any way for the performance or
non-performance of the obligations of any other Purchaser under any
Transaction Document. Nothing contained herein or in any other
Transaction Document, and no action taken by any Purchaser pursuant
hereto or thereto, shall be deemed to constitute the Purchasers as
a partnership, an association, a joint venture or any other kind of
entity, or create a presumption that the Purchasers are in any way
acting in concert or as a group with respect to such obligations or
the transactions contemplated by the Transaction Documents. Each
Purchaser shall be entitled to independently protect and enforce
its rights including, without limitation, the rights arising out of
this Agreement or out of the other Transaction Documents, and it
shall not be necessary for any other Purchaser to be joined as an
additional party in any proceeding or action for such purpose. Each
Purchaser has been represented by its own separate legal counsel in
its review and negotiation of the Transaction Documents. For
reasons of administrative convenience only, certain Purchasers and
their respective counsel have chosen to communicate with the
Company through the legal counsel of the Agent. The legal counsel
of the Agent does not represent any of the Purchasers and only
represents the Agent, which is its client. The Company has elected
to provide all Purchasers with the same terms and Transaction
Documents for the convenience of the Company and not because it was
required or requested to do so by any of the Purchasers. It is
expressly understood and agreed that each provision contained in
this Agreement and in each other Transaction Document is between
the Company and a Purchaser, solely, and not between the Company
and the Purchasers collectively and not between and among the
Purchasers.
[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK]
IN
WITNESS WHEREOF, the parties hereto have caused this Note Purchase
Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.
METASTAT, INC.
|
Address
for Notice:
|
By:__________________________________________
Name:
Title:
With a
copy to (which shall not constitute notice):
|
MetaStat, Inc.
27 Drydock Ave., 2
nd
Floor
Boston, MA 02210
Attention: Douglas A. Hamilton, CEO
Telephone No.: (617) 531-0870
Facsimile No. (646) 304-7086
Email: dhamilton@metastat.com
With an
Email copy to: dschneiderman@metastat.com
|
Loeb & Loeb LLP
345 Park Avenue
New York, NY 10154
Attention: David J. Levine, Esq.
Telephone
No.: 212-407-4923
Facsimile
No.: 212-818-1184
Email:
dlevine@loeb.com
|
|
[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK
SIGNATURE
PAGE FOR PURCHASERS FOLLOWS]
[COMPANY SIGNATURE PAGE TO NOTE PURCHASE AGREEMENT]
-22-
IN
WITNESS WHEREOF, the undersigned have caused this Note Purchase
Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.
Name of
Purchaser: ________________________
Signature of Authorized Signatory of
Purchaser
: ________________________
Name of
Authorized Signatory: ________________________
Title
of Authorized Signatory: ________________________
Purchaser’s
Tax I.D. or Social Security Number:
________________________
Email
Address of Authorized Signatory:
________________________
Phone
Number of Authorized Signatory:
________________________
Address
for Notice to Purchaser:
________________________
________________________
________________________
Address
for Delivery of Securities to Purchaser (if not same as address for
notice):
________________________
________________________
________________________
Purchase Price:
$_______________________
Note
Warrants: _______________________
[PURCHASER SIGNATURE PAGE TO NOTE PURCHASE AGREEMENT]
-23-
EXHIBIT A
TO THE NOTE PURCHASE AGREEMENT
LIST OF PURCHASERS
Close and Closing Date:
Name and Address
of Purchasers
|
Purchase Price
|
Number of Securities Purchased
|
[_____]
|
$[_____]
|
Senior
Notes: $[_____]
# Note
Warrants: [_____]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EXHIBIT B-1
TO THE NOTE PURCHASE AGREEMENT
FORM OF SENIOR NOTE
EXHIBIT B-2
TO THE NOTE PURCHASE AGREEMENT
FORM OF JUNIOR NOTE
EXHIBIT C
TO THE NOTE PURCHASE AGREEMENT
FORM OF NOTE WARRANT
EXHIBIT D
TO THE NOTE PURCHASE AGREEMENT
FORM OF EXCHANGE AGREEMENT
EXHIBIT E
TO THE NOTE PURCHASE AGREEMENT
ESCROW WIRE INSTRUCTIONS
EXHIBIT F
TO THE NOTE PURCHASE AGREEMENT
CONFIDENTIAL PRIVATE PURCHASER QUESTIONNAIRE
Exhibit
10.2
EXCHANGE AGREEMENT
This
EXCHANGE AGREEMENT (this “
Agreement
”) is made
effective as of March 30, 2018 (the “
Execution Date
”) by and
among MetaStat, Inc., a Nevada corporation (the “
Company
”) and
[___________] (the “
Investor
”).
RECITALS
WHEREAS, the
Company and the Investor entered into a securities purchase
agreement dated as of December 31, 2014, as amended on March 27,
2015 (the “
Series B
Purchase Agreement
”), pursuant to which the Company
issued and sold to the Payee: (i) shares of Series B Convertible
Preferred Stock (the “
Series B Preferred
”) with
a stated value of $5,500 per share, which is convertible into
shares of the Company’s common stock, par value $0.0001 per
share (the “
Common
Stock
”) and (ii) five-year warrants to purchase 91,000
shares of Common Stock at $10.50 per share (the “
Series A Warrants
”) for
an aggregate purchase price of $1,001,000.00;
WHEREAS, the
Company and the Investor entered into that certain Exchange
Agreement dated January 17, 2017 (the “
Exchange Agreement
”),
pursuant to which the Company issued to the Investor a 10%
convertible promissory note (the “
Promissory Note
”), in the
aggregate principal amount of $1,000,000.00, which is convertible
into shares of Common Stock at $2.00 per share, and having a
maturity date of September 30, 2017, in accordance with the terms
of the Exchange Agreement;
WHEREAS, Investor
is currently the beneficial owner of 226.2941 shares of Series B
Preferred plus accrued and unpaid dividends through March 30, 2018
in the amount of $50,116.00 for an aggregate stated value of
$1,294,900.00 (the “
Stated
Value
”);
WHEREAS, Investor
is currently the beneficial owner of the Promissory Note in the
principal amount of $1,000,000.00 plus accrued and unpaid interest
through March 30, 2018 of $134,027.00 (the “
Principal
Balance
”);
WHEREAS, the
Company is currently conducting a private placement (the
“
Private
Placement
”) pursuant to a note purchase agreement
dated on or about March 30, 2018 (the “
Note Purchase Agreement
”)
in the form attached hereto as
Exhibit A
, which consists of
(i) senior non-convertible promissory bridge notes (the
“
Senior
Notes
”), in the form attached hereto as
Exhibit B,
(ii) junior
non-convertible promissory bridge notes (the “
Junior Notes,
” and
together with the Senior Notes, the “
Notes
”), in the form
attached hereto as
Exhibit
C,
and (iii) five-year warrants with an exercise price of
$2.00 per share (the “
Note Warrants
”) to
purchase 10,000 shares of Common Stock for every $100,000 principal
amount of Notes, in the form attached hereto as
Exhibit D
. The shares of Common
Stock the Warrants are exercisable into shall be referred to as the
“
Warrant
Shares
”;
WHEREAS,
concurrently, but in no event later than two (2) business days
following the Closing (as defined below), the Company shall repay
to the Investor $300,000.00 (the “
Cash Payment
”) of the
Principal Balance, leaving $834,027.00 principal amount of the
Promissory Note remaining (the “
Note Exchange Balance
”)
for the Exchange (as defined below).
WHEREAS, the
Company desires, and the Investor agrees, that the Investor
exchange (the “
Exchange
”) the Promissory
Note, the Series B Preferred, and the Series A Warrants for the
following securities to be issued in the Private Placement: (i) a
Senior Note in the aggregate principal amount equal to $834,027.00
(the Note Exchange Balance), (ii) a Junior Note in the aggregate
principal amount equal to $1,294,900.00 (the Stated Value), and
(iii) Warrants to purchase an aggregate of 212,893 shares of Common
Stock (the “
Note
Warrants
”), upon the terms and conditions set forth
herein and shall be deemed a purchaser under the Note Purchase
Agreement;
WHEREAS, each of
the Notes, the Note Warrants, and the Warrant Shares is intended to
qualify as an exempted security under Section 3(a)(9) or Section
4(a)(2) of the Securities Act of 1933, as amended (the
“
Securities
Act
”).
AGREEMENT
NOW,
THEREFORE, in consideration of the mutual covenants contained in
this Agreement, and for other good and valuable consideration the
receipt and adequacy of which are hereby acknowledged, the Company
and the Investor agree as follows:
ARTICLE I
THE EXCHANGE
1.1
Closing
.
Subject to the terms and conditions set forth in this Agreement,
the Company and the Investor shall exchange (i) the Promissory Note
in consideration for the issuances of a Senior Note in the
aggregate principal amount equal to $834,027.00 (the Note Exchange
Balance) and 83,403 Note Warrants, and (ii) the Series B Preferred
and the Series A Warrant in consideration for the issuances of a
Junior Note in the aggregate principal amount equal to
$1,294,900.00 (the Stated Value), and 129,490 Note Warrants. The
closing of the Exchange and issuance of the Notes and Note Warrants
(the “
Closing
”) shall take
place at the offices of the Company, 27 Drydock Ave., 2
nd
Floor, Boston, MA
02210 on the date hereof or such other date as the parties shall
agree (the “
Closing
Date
”).
1.2
Exchange
.
(a)
Investor Obligations
. At the
Closing, the Investor shall deliver or promptly cause to be
delivered to the Company (i) the original Promissory Note, (ii) the
certificates representing the Series B Preferred, or an
indemnification undertaking with respect to such certificates in
the event of the loss, theft or destruction of such certificates
(iii) an executed copy of this Agreement, and (iv) an executed copy
of the Note Purchase Agreement and any other related Private
Placement documents.
(b)
Company Obligations
. At the
Closing, the Company shall deliver or promptly cause to be
delivered to the Investor (i) the Notes, (ii) the Note Warrants,
(iii) an executed copy of this Agreement, and (iv) an executed copy
of the Note Purchase Agreement and any other related Private
Placement documents. Promptly, but in no event later than two (2)
business days following the Closing, the Company shall pay the Cash
Payment of $300,000.00 to the Investor, according to written wire
instructions provided by the Investor to the Company attached
hereto on
Exhibit
E,
or otherwise agreed to by the parties.
(c)
Promissory Note, Series B
Preferred and Series A Warrant
. Effective as of the Closing
Date, the Promissory Note, the Series B Preferred and the Series A
Warrant shall be deemed automatically canceled and of no further
force or effect and shall thereafter represent only the right to
receive the Notes and Note Warrants (sometimes collectively
referred to herein as the “
New Securities
”), and the
Cash Payment .
ARTICLE II
REPRESENTATIONS AND WARRANTIES
2.1
Investor
Representations and Warranties
. The Investor hereby
represents and warrants to the Company as follows on the Execution
Date and the Closing Date:
(a)
Organization;
Authority
. The Investor, if not a natural person, is an
entity duly organized, validly existing and in good standing under
the laws of the jurisdiction of its organization. The Investor has
the requisite power and authority to enter into and to consummate
the transactions contemplated by this Agreement and otherwise to
carry out its obligations hereunder. This Agreement has been duly
executed by the Investor, and when delivered by the Investor in
accordance with the terms hereof, will constitute the valid and
legally binding obligation of the Investor, enforceable against it
in accordance with its terms.
(b)
Ownership of the
Promissory Note, Series B Preferred and Series A Warrant
.
The Investor is the sole owner of the Promissory Note, the Series B
Preferred, and the Series A Warrant free and clear of any and all
liens, claims and encumbrances of any kind.
(c)
Investment Intent
. The Investor
is acquiring the New Securities as principal for its own account
for investment purposes only and not with a view to or for
distributing or reselling such New Securities or any part thereof,
except pursuant to sales that are exempt from the registration
requirements of the Securities Act and/or sales registered under
the Securities Act. The Investor does not have any agreement or
understanding, directly or indirectly, with any person or entity to
distribute the New Securities.
(d)
Investor Status
. At the time
the Investor was offered the New Securities, it was, and at the
date hereof it is, an “accredited investor” as defined
in Rule 501(a) of Regulation D under the Securities Act. The
Investor is not a broker-dealer.
(e)
General Solicitation
. The
Investor is not acquiring the New Securities as a result of or
subsequent to any advertisement, article, notice or other
communication regarding the New Securities published in any
newspaper, magazine or similar media or broadcast over television
or radio or presented at any seminar or any other general
solicitation or general advertisement.
(f)
Reliance
. The Investor
understands and acknowledges that (i) the New Securities are
being offered and sold to it without registration under the
Securities Act in a transaction that is exempt from the
registration provisions of the Securities Act, and (ii) the
availability of such exemption depends in part on, and the Company
will rely upon the accuracy and truthfulness of, the foregoing
representations, and the Investor hereby consents to such
reliance.
(g)
Brokers and Finders
. The
Investor has no knowledge of any person who will be entitled to or
make a claim for payment of any finder fee or other compensation as
a result of the consummation of the transactions contemplated by
this Agreement.
2.2
Company
Representations and Warranties
. The Company hereby makes the
following representations and warranties to each Investor on the
Execution Date and on the Closing Date:
(a)
Organization and Qualification
.
The Company is a corporation incorporated, validly existing and in
good standing under the laws of the State of Nevada, with the
requisite corporate power and authority to own and use its
properties and assets and to carry on its business as currently
conducted. The Company is duly qualified as a foreign corporation
to do business and is in good standing in every jurisdiction where
the nature of the business it conducts makes such qualification
necessary, except where the failure to do so would not have a
material adverse effect on the Company.
(b)
Authorization; Enforcement
. The
Company has the requisite corporate power and authority to enter
into and to consummate the transactions contemplated by this
Agreement and to issue the Notes, the Note Warrants and Warrant
Shares, upon exercise of the Note Warrants in accordance with the
terms of the Note Warrants and otherwise to carry out its
obligations hereunder and thereunder. The execution, delivery and
performance of this Agreement and any other agreements and the
consummation of the transactions contemplated hereby and thereby
have been duly authorized by the Company’s Board of
Directors, and no further consent or authorization of the Company,
its Board of Directors (including any committee thereof) or any
class of the Company’s stockholders is required. This
Agreement, the Notes, and the Note Warrants have been duly executed
by the Company and, when delivered in accordance with the terms
hereof, will constitute the valid and binding obligations of the
Company enforceable against the Company, in accordance with their
terms, except: (i) as limited by general equitable principles and
applicable bankruptcy, insolvency, reorganization, moratorium and
other laws of general application affecting enforcement of
creditors’ rights generally, (ii) as limited by laws relating
to the availability of specific performance, injunctive relief or
other equitable remedies and (iii) insofar as indemnification and
contribution provisions may be limited by applicable
law.
(c)
Issuance of the New Securities
.
The Notes and the Note Warrants, when issued at the Closing, will
be duly authorized, validly issued, fully paid and non-assessable
and will be free and clear of all taxes, liens, options or other
encumbrances of any nature (except for those imposed under
applicable securities laws).
(d)
No Conflicts
. The execution,
delivery and performance of this Agreement, and the consummation by
the Company of the transactions contemplated hereby and thereby
(including, without limitation, the issuance and reservation for
issuance, as applicable, of the Warrant Shares will not, (i) result
in a violation of the certificate of incorporation of the Company
(the “
Certificate of
Incorporation
”) or the bylaws of the Company (the
“
Bylaws
”) or (ii) result
in a violation of any law, rule, regulation, order, judgment or
decree (including United States federal and state securities laws
and regulations and rules or regulations of any self-regulatory
organizations to which either the Company or its securities are
subject) applicable to the Company or by which any property or
asset of the Company is bound or affected. The Company is not in
violation of its Certificate of Incorporation, Bylaws or other
organizational documents. The Company is not in default (and no
event has occurred which, with notice or lapse of time or both,
would put the Company in default) under, nor has there occurred any
event giving others (with notice or lapse of time or both) any
rights of termination, amendment, acceleration or cancellation of,
any agreement, indenture or instrument to which the Company is a
party except for such violations, defaults or events that have had
a material adverse effect.
(e)
Absence of Certain Changes
.
Since February 28, 2017, there has been no material adverse change
and no material adverse development in the business, properties,
operations, prospects, financial condition or results of operations
of the Company, except as disclosed in the reports, schedules,
forms, statements and other documents (including all financial
statements and schedules thereto and all exhibits included therein
and documents incorporated by reference therein) required to be
filed by the Company with the Securities and Exchange Commission
(the “
SEC
”) pursuant to the
reporting requirements of the Securities Exchange Act of 1934, as
amended, filed before the date hereof. The Company has not taken
any steps, and does not currently expect to take any steps, to seek
protection pursuant to any bankruptcy or receivership law nor does
the Company have any knowledge or reason to believe that its
creditors intend to initiate involuntary bankruptcy proceedings
with respect to the Company.
(f)
Certain Fees
. No fees or
commissions will be payable by the Company to any broker, financial
advisor or consultant, finder, placement agent, investment banker,
bank or other Person with respect to the transactions contemplated
by this Agreement.
ARTICLE III
OTHER COVENANTS
3.1
Securities
Laws
. The Investor acknowledges that the Notes, Note
Warrants and Warrant Shares have not been registered under the
Securities Act and may only be disposed of pursuant to an available
exemption from or in a transaction not subject to the registration
requirements of the Securities Act.
3.2
Restrictive
Legend
. The Investor agrees to the imprinting of the
following legend, or in similar form, on the Notes, Note Warrants
and Warrant Shares:
THESE
SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND
EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN
RELIANCE UPON AN EXEMPTION FROM REGISTRATION, AND, ACCORDINGLY, MAY
NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OF 1933 AND APPLICABLE STATE
SECURITIES LAWS OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A
TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE
SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES
LAWS.
3.3
Reservation of
Shares
. The Company shall at all times have authorized and
reserved for the purpose of issuance a sufficient number of Warrant
Shares.
ARTICLE IV
MISCELLANEOUS
4.1
Fees
and Expenses
. Except as set forth in this Section 4.1, each
party shall pay the fees and expenses of its advisers, counsel,
accountants and other experts, if any, and all other expenses
incurred by such party incident to the negotiation, preparation,
execution, delivery and performance of this Agreement. The Company
shall pay all stamp and other taxes and duties levied in connection
with the issuance of the New Securities.
4.2
Entire
Agreement; Amendments
. This Agreement together with the
exhibits and schedules hereto, dated as of the Execution Date,
contains the entire understanding of the parties with respect to
the subject matter hereof and supersedes all prior agreements and
understandings, oral or written, with respect to such matters,
which the parties acknowledge have been merged into such documents,
exhibits and schedules.
4.3
Notices
.
Any and all notices or other communications or deliveries required
or permitted to be provided hereunder shall be in writing and shall
be deemed given and effective on the earliest of (i) the date of
transmission, if such notice or communication is delivered via
facsimile at the facsimile number or email at the email address
specified in this Section prior to 6:00 p.m. (New York City time)
on a business day, against electronic confirmation thereof, (ii)
the business day after the date of transmission, if such notice or
communication is delivered via facsimile at the facsimile number or
email at the email address specified in this Agreement later than
6:00 p.m. (New York City time) on any date, against electronic
confirmation thereof, (iii) the business day following the date of
mailing, if sent by nationally recognized overnight courier
service, or (iv) upon actual receipt by the party to whom such
notice is required to be given. The address for such notices and
communications shall be as follows:
If to the
Company:
MetaStat,
Inc.
27
Drydock Ave., 2
nd
Floor
Boston,
MA 02210
Facsimile No.:
(646) 304-7086
Email:
dschniederman@metastat.com
Attn:
Daniel Schneiderman
With
copies to (which
shall
Loeb & Loeb LLP
not constitute
notice):
345 Park Ave.
New
York, NY 10154
Facsimile No.:
(212) 898-1184
Email:
dlevine@loeb.com
Attn:
David Levine
If to the
Investor:
[___________]
[___________]
[___________]
Attention:
[___________]
Tel.
No.: [___________]
Fax
No.: [___________]
Email:
[___________]
or such
other address as may be designated in writing hereafter, in the
same manner, by such person or entity.
4.4
Amendments;
Waivers
. No provision of this Agreement may be waived or
amended except in a written instrument signed, in the case of an
amendment, by the Company and by the Investor. No waiver of any
default with respect to any provision, condition or requirement of
this Agreement shall be deemed to be a continuing waiver in the
future or a waiver of any other provision, condition or requirement
hereof, nor shall any delay or omission of either party to exercise
any right hereunder in any manner impair the exercise of any such
right accruing to it thereafter.
4.5
Headings
.
The headings herein are for convenience only, do not constitute a
part of this Agreement and shall not be deemed to limit or affect
any of the provisions hereof.
4.6
Successors
and Assigns
. This Agreement shall be binding upon and inure
to the benefit of the parties and their successors and permitted
assigns. The Investor may not assign this Agreement or any rights
or obligations hereunder without the prior written consent of the
Company.
4.7
No
Third-Party Beneficiaries
. This Agreement is intended for
the benefit of the parties hereto and their respective successors
and permitted assigns and is not for the benefit of, nor may any
provision hereof be enforced by, any other person or
entity.
4.8
Governing
Law
. This Agreement shall be governed by and construed and
enforced in accordance with the internal laws of the State of New
York, without regard to the principles of conflicts of law thereof.
The Company and the Investor irrevocably consent to the
jurisdiction of the United States federal courts and state courts
located in the State of New York in any suit or proceeding based on
or arising under this Agreement and irrevocably agree that all
claims in respect of such suit or proceeding may be determined in
such courts.
4.9
Survival
.
The representations and warranties contained herein shall survive
until the expiration of the first anniversary following the
Closing. The agreements and covenants contained herein shall
survive the Closing and the delivery of the New Securities until
the expiration of the applicable statute of limitations (if any)
therefor.
4.10
Execution
.
This Agreement may be executed in one or more counterparts, all of
which when taken together shall be considered one and the same
agreement and shall become effective when counterparts have been
signed by each party and delivered to the other party, it being
understood that all parties need not sign the same counterpart. In
the event that any signature is delivered by facsimile transmission
or a scanned copy via electronic mail, such signature shall create
a valid and binding obligation of the party executing (or on whose
behalf such signature is executed) the same with the same force and
effect as if such facsimile or scanned signature page were an
original thereof.
4.11
Severability
.
In case any one or more of the provisions of this Agreement shall
be invalid or unenforceable in any respect, the validity and
enforceability of the remaining terms and provisions of this
Agreement shall not in any way be affected or impaired thereby and
the parties will attempt to agree upon a valid and enforceable
provision which shall be a reasonable substitute therefor, and upon
so agreeing, shall incorporate such substitute provision in this
Agreement.
4.12
Further
Assurances
. The parties hereto agree that each shall execute
and deliver any and all further agreements, instruments,
certificates and other documents, and shall take any and all
action, as any of the parties hereto may reasonably deem necessary
or desirable in order to carry out the intent of the parties to
this Agreement.
4.13
Attorneys’
Fees
. If either party shall commence an action or proceeding
to enforce any provisions relating to the obligations to close the
transactions contemplated by this Agreement prior to the Closing,
then the prevailing party in such action or proceeding shall be
reimbursed by the other party for its attorneys’ fees and
other costs and expenses incurred with the investigation,
preparation and prosecution of such action or
proceeding.
[
signature
page follows
]
IN
WITNESS WHEREOF, the parties hereto have caused this Exchange
Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.
COMPANY:
METASTAT,
INC.
By:
___________________________
Name:
Title:
INVESTOR:
By:
______________________________
Name:
Title:
[Signature
Page to Exchange Agreement]
-7-
Exhibit A
[Form of Note Purchase Agreement]
Exhibit B
[Form
of Senior Note]
Exhibit C
[Form
of Junior Note]
Exhibit D
[Form
of Note Warrant]
Exhibit E
[Wire
Instructions]